

10-31-00

A

Docket No. 5143

Box Patent Application  
 Assistant Commissioner of Patents  
 Washington, D.C. 20231

jc813 U.S. PTO  
 09/699732  
 10/30/00

## NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of :

Inventor(s): Michael J. Hearn

For (title): Antimycobacterial Compounds and Method for Making The Same

**1. Type of Application**

- ☒ Utility  
☐ Design

**2. Benefit of Prior U.S. Application(s) Under 35 U.S.C. §120**

This application is a:

- ☐ Divisional  
☐ Continuing Patent Application (CPA)  
☐ Continuation-in-part (CIP),

and hereby claims benefit under 35 U.S.C. §120 to the following applications:

SERIAL NUMBER	FILING DATE
None	

**3. Benefit of Non-U.S. Application Under 35 U.S.C. §119(a)-(d)**

This application claims priority under 35 U.S.C. §119(a)-(d) to the following foreign application(s) and/or inventor certificate(s):

COUNTRY	APPLN. NUMBER	FILING DATE
None		

Certified copy(ies) of the application(s) and/or inventor certificate's from which priority is claimed:

- ☐ is(are) attached;  
☐ will follow.

**4. Benefit of Provisional Application Under 35 U.S.C. §119(e)**

This application claims priority to the following provisional application(s):

SERIAL NUMBER	FILING DATE
None	

-----  
**CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10**

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date October 30, 2000 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL662368573US addressed to the: Assistant Commissioner of Patents, Washington, D.C. 20231.

*Julie A. Catalano*  
 Julie A. Catalano

**5. Papers Enclosed Which Are Required For Filing Date Under 37 C.F.R. §1.53**

114 Pages of Specification, including claims and abstract

2 Sheets of Drawing

**6. Additional Papers Enclosed**

- ☐ Declaration and Power of Attorney
- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement (37 CFR 1.98), Form PTO-1449 and a copy of each cited reference
- ☐ Assignment
- ☐ Small Entity Declaration
- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing" computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequences.
- ☐ Other

## 7. Application Filing Fee Calculation

A. ☒ Utility Application

**FEE CALCULATION:**

<b>Total Claims:</b>	20 - 20 =	0×\$18 =	\$ 0
<b>Independent Claims:</b>	7 - 3 =	4×\$80 =	\$ 320.00
<b>Basic Fee:</b>			\$ 710.00
<b>Multiple-Dependent-Claim Fee :</b>			\$ 0

Total of the Above Calculations:.....	\$1,030.00
---------------------------------------	------------

- ☐ Amendment canceling extra claims enclosed.
- ☐ Amendment deleting multiple dependencies enclosed.
- ☐ Fee for extra claims is not being paid at this time.

<b>B.</b>	<input type="checkbox"/>	Design application - \$310	\$
		Application Filing Fee Sub-Total .....	\$
<b>C.</b>	<input type="checkbox"/>	Less 50% reduction for small entity.....	\$
<b>D.</b>	<input type="checkbox"/>	Non-English Specification - \$130.....	\$

**TOTAL FILING FEE ..... \$1,030.00**

8. **Payment**



Enclosed



Check in the amount of the Total Filing Fee set forth above.



Charge Account No. 19-0079 in the amount of Total Filing Fee set forth above. A duplicate of this transmittal is attached.




Not Enclosed

**WARNING:** If no fees are to be paid at the time of filing the application, the following paragraph must be deleted.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 that may be required by this paper or any paper filed in connection with this Patent Application, or refund any overpayment payable to Samuels, Gauthier & Stevens, LLP at the address set forth below.

Respectfully submitted,



Reg. No. 44,357

For:

Richard L. Stevens

Reg. No. 24,445

Samuels, Gauthier & Stevens

225 Franklin Street, Suite 3300

Boston, MA. 02110

(617) 426-9180, Ext. 122

05669732 103000

## Title of the Invention

Antimycobacterial compounds and method for making the same

## Background of the Invention

5

### 1. Field of the Invention

10

The present invention relates to novel antimycobacterial compounds and in particular to antimycobacterial compounds comprised of Schiff base, diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

### 2. Description of the Related Art

15

The occurrence of some three million new cases of tuberculosis per year world-wide and the emergence of new strains of *Mycobacterium tuberculosis* characterized by drug resistance or increased virulence have created the need for the evolution of newer and more powerful drugs, the re-examination and re-evaluation of prior art drugs and the detailed elucidation of the mechanisms of action of antimycobacterial compounds.

20

In the United States there has been an increase in the incidence of tuberculosis between 1985 and 1992. As many as 15 million persons in the United States are probably infected but are not yet symptomatic. These persons may develop active disease, and their risk for so doing increases when coinfectd with the human immunodeficiency virus (HIV). Infection with *Mycobacterium tuberculosis* is observed to a significant extent among acquired immune deficiency syndrome (AIDS) patients or among individuals undergoing immunosuppressive therapy. Significantly, tuberculosis accelerates the natural history of HIV, particularly in the early stages of infection, resulting in an increased viral load. Tuberculosis may generate a nurturing microenvironment for HIV, enhancing viral replication. While many cases of disease

25

due to pathogenic mycobacteria are caused by *Mycobacterium tuberculosis* (MTB), several other mycobacterial diseases have begun to emerge, caused by nontuberculous mycobacteria (NTB). These include diseases caused by *Mycobacterium avium*, *M. ulcerans*, *M. marinum* and *M. haemophilum*. These NTM diseases are considered important opportunistic infections (OIs) in patients with AIDS, but the rates of non-AIDS-associated NTB infections are also on the rise.

An absence of activity by those skilled in the art in the area of new drug development extending over a period of approximately 35 years has led to minimal research relating to the design of new antimycobacterial agents. This lack of research is a result of the usefulness and efficacy of prior art drugs such as isoniazid (INH, the most widely used antimycobacterial drug), ethambutol, rifampin and pyrazinamide. Combination therapy involving these drugs, especially when prescribed as one component of a broader therapeutic regimen such as directly-observed short-course therapy (DOTS), has been highly effective. When the goal of the elimination of tuberculosis seemed achievable, based largely on these effective drugs and improving standards of nutrition, hygiene and public health, little impetus remained for research.

Today, it is clear that increased research on drug design has been necessary to recapture lost ground and to make new advances. To facilitate the development of new antimycobacterials, those skilled in the art have recently begun to place strong emphasis on the identification of the targets of existing drugs and on those characteristics of pathogen cell wall structure that play a role in limiting drug effectiveness. Billington et al., Synthesis and Antimycobacterial Activity of Some Heteroarylcarboxamidrazone Derivatives. Drug Design and Discovery. 15:269-275 (1998); Setlow P., Survival of Dormant Spores of *Bacillus* Species for Years and Years and.... How Do They Do It? The Nucleus. LXXIII:5 (1995); Wallis et al., Drug Tolerance in *Mycobacterium tuberculosis*. Antimicrobial Agents and Chemotherapy. 43(11):2600-2606 (1999). For example, one target enzyme for INH is a long-chain enoyl-acyl

carrier protein (ACP) reductase (InhA). This enzyme is important for the biosynthesis of mycolic acids, alpha-branched fatty acids containing as many as 90 carbon atoms, crucial components of mycobacterial cell walls. Asselineau, J. et al., Chemical Structure and Biological Activity of Mycolic Acids, p. 14ff, 40. *In* C. Wolstenholme, M. Cameron, and C. O'Connor (ed.), Ciba Foundation Symposium on Experimental Tuberculosis: Bacillus and Host (with an Addendum on Leprosy)(1955); Brennan, P. et al., The Envelope of Mycobacteria. Annual Reviews in Biochemistry. 64:29-63 (1995).

The present invention provides novel Schiff base, diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide that have increased lipophilicity and inhibit mycolate biosynthesis.

In addition to the need for the evolution of newer and more powerful antimycobacterial drugs, the biological evaluation of compounds suspected to be active against mycobacteria requires that the compounds be readily available in pure form on quantity scale, generally understood to be gram or multi-gram scale, as opposed to milligram scale. Gram scale quantities are necessary for the large numbers of biological tests which must be performed and replicated for the evaluation of a new drug candidate.

Products of synthetic reactions are most desirable when they can be easily and cheaply obtained as dry and free-flowing solids. In the long run, dry and free-flowing solids permit better formulations of drugs as tablets, capsules or syrups. The invention disclosed herein provides a novel method of Schiff base synthesis which yields products directly as dry free-flowing solids in analytically pure form. The products of the prior art syntheses are obtained as intractable oils which are difficult and labor-intensive to purify or bring into dry free-flowing form. The present invention overcomes these drawbacks and provides syntheses of Schiff base,

diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide, which yield products that are suitable for biological evaluation.

#### Brief Summary of the Invention

5 Broadly, this invention comprises compositions having efficacy against mycobacterial infections. One aspect of the invention comprises the rational design of more potent and less toxic antimycobacterial drugs using synthetic organic chemistry. Such drugs can achieve improved outcome against mycobacteria by increasing drug lipophilicity. Rational design choices allow the inclusion into drug structure of elements promoting diffusion across the mycobacterial cell wall through the lipid domain. The resulting enhanced activity will permit lower dosing and greater tolerance by the host. In addition to the lipophilic units, the structures of many of these compounds also incorporated multiple-bonding sites which render them potential substrates for reductases and thus possible oxidative stressors of mycobacteria.

10 Another aspect of the invention comprises the reliable and reproducible methods for the synthesis of these compounds on such a scale and in such purity as to be suitable for subsequent biological evaluations, such as evaluations using near infrared spectroscopy (NIR), so compounds can be readily obtained on multigram scale and in good purity. The syntheses of the invention obviate the need for special drying, mulling or pelleting of samples for spectrometric techniques, such as mid-range infrared spectroscopy. Also within the scope of the invention is a method for quantitative estimates of the relative lipophilicities of the antimycobacterial compounds which comprises partitioning the antimycobacterial compounds between organic and aqueous phases in biphasic liquid-liquid extraction. Antimycobacterial compounds can be isolated from each of the phases, and the ratio of amounts in each phase can be compared to a similar ratio for INH as standard.

Another aspect of this invention comprises the syntheses for the preparation of Schiff base, diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide.


Yet another aspect of this invention comprises the intermediates useful in the syntheses of Schiff base, diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide.

The present invention provides useful antimycobacterial compounds which are effective against a number of species of mycobacteria.

Another aspect of the invention provides useful antimycobacterial compounds which are unexpectedly effective against *Mycobacterium tuberculosis*, *Mycobacterium kansasii*, and *Mycobacterium avium*.

This invention also comprises pharmaceutical compositions containing Schiff base, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide and their use as therapeutic agents for the treatment of mycobacterial infections.

Another aspect of the invention comprises the formula:



wherein  $R_1$  is H; and

$R_2$  is  $C_3$  to  $C_{14}$  alkyl,  $C_3$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy;



or a pharmaceutically acceptable salt thereof; or a pharmaceutical isomer thereof; or a combination of the same.

Another embodiment of the invention comprises formula I

wherein  $R_1 = H$ , and  $R_2$  is  $CH=CHCH_3$  (trans),  $CH=CHCH_2CH_3$  (trans),  $CH=CHCH_2CH_2CH_3$  (trans),  $CH=CHCH_2CH_2CH_2CH_3$  (trans),  $C(CH_3)=CHCH_3$  (trans),  $CH=C(CH_3)CH_2CH_2CH=C(CH_3)_2$  (trans),  $CH=NNHCO-4-C_5H_9N$ ,  $CH_2CH(CH_3)CH_2CH_2CH=C(CH_3)_2$ ,  $4-C_6H_4-CH=NNHCO-4-C_5H_9N$ ,  $4-C_6H_4-O-CH_2CH_2CH_2CH_3$ ,  $(CH_2)_{11}CH_3$ ,  $4-C_6H_4NO_2$ ,  $C_6H_5$ ,  $2-C_6H_4OH$ ,  $4-OH-3-OCH_3C_6H_3$ ,  $4-C_6H_4OCH_3$ ,  $3-C_6H_4OCH_3$ ,  $(CH_2)_8CH_3$ ,  $(CH_2)_2CH_3$ ,  $2-C_6H_4OCH_3$ ,  $C(CH_3)=CHC_6H_5$  (trans),  $4-C_6H_4F$ ,  $3,5-di(CH_3)-4-O-C_7H_7$ ,  $2-F-4-OCH_3C_6H_3$ ,  $2-ClC_6H_4$ ,  $4-BrC_6H_4$ ,  $3-C_6H_4NO_2$ ,  $4-C_6H_4O(CH_2)_5CH_3$ ,  $2-Cl-5-NO_2C_6H_3$ ,  $4-Cl-3-NO_2C_6H_3$ ,  $2-C_6H_4NO_2$ ,  $2,6-di(Cl)C_6H_3$ ,  $2,3-di(Cl)C_6H_3$ ,  $C_6H_5$ ,  $3,4-di(F)C_6H_3$ ,  $2,6-di(F)C_6H_3$ ,  $3,4-di(Cl)C_6H_3$ ,  $4-C_6H_4Cl$ , or  $CH=C(C_6H_5)_2$ .

Yet another embodiment of the invention comprises formula I wherein  $R_1$  is  $CH_3$  and  $R_2 = CH_2COCH_3$  or  $C_6H_5$ .

In yet another embodiment, the invention comprises formula I wherein  $R_1$  is  $CH_2CO_2CH_2CH_3$  and  $R_2$  is  $CH_2CH_2CH_3$  or  $CH_3$ .

Yet another embodiment of the invention comprises formula I wherein  $R_1$  is  $CO_2CH_2CH_3$  and  $R_2$  is  $CH_2CH_2C_6H_5$ .


Another embodiment of the invention comprises formula I wherein  $R_1$  is  $2-C_5H_4N$  and  $R_2$  is  $2-C_5H_4N \cdot 2H_2O$ .


Yet another embodiment of the invention comprises formula I where  $R_1, R_2$  is  $(CH_2)_4$ ,  $(CH_2)_6$ ,  $4-C_6H_8NNHCO-4-C_5H_4N$ .

a) $\alpha = 0.05$		b) $\alpha = 0.01$	
$\alpha$	0.05	$\alpha$	0.01
$\beta$	0.05	$\beta$	0.01
$\gamma$	0.05	$\gamma$	0.01
$\delta$	0.05	$\delta$	0.01
$\epsilon$	0.05	$\epsilon$	0.01
$\zeta$	0.05	$\zeta$	0.01
$\eta$	0.05	$\eta$	0.01
$\theta$	0.05	$\theta$	0.01
$\iota$	0.05	$\iota$	0.01
$\kappa$	0.05	$\kappa$	0.01
$\lambda$	0.05	$\lambda$	0.01
$\mu$	0.05	$\mu$	0.01
$\nu$	0.05	$\nu$	0.01
$\xi$	0.05	$\xi$	0.01
$\omicron$	0.05	$\omicron$	0.01
$\pi$	0.05	$\pi$	0.01
$\rho$	0.05	$\rho$	0.01
$\sigma$	0.05	$\sigma$	0.01
$\tau$	0.05	$\tau$	0.01
$\upsilon$	0.05	$\upsilon$	0.01
$\phi$	0.05	$\phi$	0.01
$\chi$	0.05	$\chi$	0.01
$\psi$	0.05	$\psi$	0.01
$\omega$	0.05	$\omega$	0.01
$\alpha$	0.05	$\alpha$	0.01
$\beta$	0.05	$\beta$	0.01
$\gamma$	0.05	$\gamma$	0.01
$\delta$	0.05	$\delta$	0.01
$\epsilon$	0.05	$\epsilon$	0.01
$\zeta$	0.05	$\zeta$	0.01
$\eta$	0.05	$\eta$	0.01
$\theta$	0.05	$\theta$	0.01
$\iota$	0.05	$\iota$	0.01
$\kappa$	0.05	$\kappa$	0.01
$\lambda$	0.05	$\lambda$	0.01
$\mu$	0.05	$\mu$	0.01
$\nu$	0.05	$\nu$	0.01
$\xi$	0.05	$\xi$	0.01
$\omicron$	0.05	$\omicron$	0.01
$\pi$	0.05	$\pi$	0.01
$\rho$	0.05	$\rho$	0.01
$\sigma$	0.05	$\sigma$	0.01
$\tau$	0.05	$\tau$	0.01
$\upsilon$	0.05	$\upsilon$	0.01
$\phi$	0.05	$\phi$	0.01
$\chi$	0.05	$\chi$	0.01
$\psi$	0.05	$\psi$	0.01
$\omega$	0.05	$\omega$	0.01
$\alpha$	0.05	$\alpha$	0.01
$\beta$	0.05	$\beta$	0.01
$\gamma$	0.05	$\gamma$	0.01
$\delta$	0.05	$\delta$	0.01
$\epsilon$	0.05	$\epsilon$	0.01
$\zeta$	0.05	$\zeta$	0.01
$\eta$	0.05	$\eta$	0.01
$\theta$	0.05	$\theta$	0.01
$\iota$	0.05	$\iota$	0.01
$\kappa$	0.05	$\kappa$	0.01
$\lambda$	0.05	$\lambda$	0.01
$\mu$	0.05	$\mu$	0.01
$\nu$	0.05	$\nu$	0.01
$\xi$	0.05	$\xi$	0.01
$\omicron$	0.05	$\omicron$	0.01
$\pi$	0.05	$\pi$	0.01
$\rho$	0.05	$\rho$	0.01
$\sigma$	0.05	$\sigma$	0.01
$\tau$	0.05	$\tau$	0.01
$\upsilon$	0.05	$\upsilon$	0.01
$\phi$	0.05	$\phi$	0.01
$\chi$	0.05	$\chi$	0.01
$\psi$	0.05	$\psi$	0.01
$\omega$	0.05	$\omega$	0.01
$\alpha$	0.05	$\alpha$	0.01
$\beta$	0.05	$\beta$	0.01
$\gamma$	0.05	$\gamma$	0.01
$\delta$	0.05	$\delta$	0.01
$\epsilon$	0.05	$\epsilon$	0.01
$\zeta$	0.05	$\zeta$	0.01
$\eta$	0.05	$\eta$	0.01
$\theta$	0.05	$\theta$	0.01
$\iota$	0.05	$\iota$	0.01
$\kappa$	0.05	$\kappa</$	




5







,



,



or




.

000001 28265950

5

Another embodiment of the invention comprises the formula:



wherein R<sub>1</sub> is H; R<sub>2</sub> is C<sub>3</sub> to C<sub>14</sub> alkyl, C<sub>3</sub> to C<sub>10</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>9</sub> substituted alkenyl, C<sub>2</sub> to C<sub>9</sub> substituted dialkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle; and

R<sub>3</sub> is C<sub>1</sub> or C<sub>2</sub> alkyl; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable isomer thereof; or a combination of the same.


Yet another embodiment of the invention comprises formula **II** wherein R<sub>1</sub> is H, R<sub>2</sub> is 2,6-di(Cl)C<sub>6</sub>H<sub>3</sub>, 3-NO<sub>2</sub>-4-Cl-C<sub>6</sub>H<sub>3</sub>, 3,4-di(F)C<sub>6</sub>H<sub>3</sub>, 2-C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>, 3,4-di(Cl)C<sub>6</sub>H<sub>3</sub> and 2,6-di(F)C<sub>6</sub>H<sub>3</sub> and R<sub>3</sub> is CH<sub>3</sub>.

Yet another embodiment of the invention comprises formula **II** wherein R<sub>1</sub> is CH<sub>3</sub>; R<sub>2</sub> is CH<sub>3</sub> and R<sub>3</sub> is CH<sub>2</sub>CH<sub>3</sub> or CH<sub>3</sub>.

Another embodiment of the invention comprises formula **II** wherein R<sub>1</sub>, R<sub>2</sub> is (CH<sub>2</sub>)<sub>5</sub> and R<sub>3</sub> is CH<sub>3</sub>.

Yet another embodiment of the invention comprises formula **II** wherein R<sub>1</sub> is CH<sub>3</sub>, R<sub>2</sub> is C<sub>6</sub>H<sub>5</sub> and R<sub>3</sub> is CH<sub>3</sub>.

Another embodiment of the invention comprises the formula:



wherein R<sub>1</sub> is C<sub>2</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>10</sub> substituted alkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;


or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable isomer thereof;

or a combination of the same.

Yet another embodiment of the invention comprises formula **III** wherein R<sub>1</sub> is NHC<sub>6</sub>H<sub>5</sub>, NH-4-C<sub>6</sub>H<sub>4</sub>CH<sub>3</sub>, NH-4-C<sub>6</sub>H<sub>4</sub>Br or NH-4-C<sub>6</sub>H<sub>4</sub>Cl.

The compounds of the present invention show enhanced and unexpected activity against several species of mycobacteria.


One embodiment the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from


the group consisting of *M.avium* and *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.avium* and *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.avium* and *M.tuberculosis*.


5 Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.avium* and *M.tuberculosis*.


10

Another embodiment of the invention comprises a compound of the formula:



15 wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.avium* and *M.tuberculosis*.


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from

the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from

the group consisting of *M.tuberculosis*.




Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

5


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

15


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

5


Another embodiment of the invention comprises a compound of the formula:



10

wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.


5

Another embodiment of the invention comprises a compound of the formula:



10 wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.


15 Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against *M.tuberculosis*, *M.avium* and *M.Kansasii*.

5

Another embodiment of the invention comprises a compound of the formula:




10

wherein the compound exhibits unexpected activity against *M.tuberculosis*, *M.avium* and *M.Kansasii*.

15


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

5


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

15


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

5


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis* and *M.avium*.

15


Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis* and *M.avium*.

5

Another embodiment of the invention comprises a compound of the formula:




10

wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*, *M.kansasii* and *M.avium*.

15

Another embodiment of the invention comprises a compound of the formula:






wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.kansasii*.

5

Yet another embodiment of the invention comprises a compound of the formula:




10

wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis* and *M.avium*.


15

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from  
 5 the group consisting of *M.tuberculosis* and *M.avium*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from  
 the group consisting of *M.avium*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Yet another embodiment of the invention comprises a compound of the formula:




wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Another embodiment of the invention comprises a compound of the formula:



wherein the compound exhibits unexpected activity against mycobacteria selected from the group consisting of *M.tuberculosis*.

Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.


It is to be understood that certain compounds of the formulas **I**, **II** and **III** can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is also to be understood that the invention encompasses all such solvated forms which possess antimycobacterial activity.

It is also to be understood that the invention relates to all tautomeric forms of compound of formulas **I**, **II**, and **III** that possess antimycobacterial activity. More particularly, it is to be understood that the invention encompasses all optical, diastereo- and regio-isomers of formulas

**I, II, and III** that possess antimycobacterial activity.

Another aspect of the invention relates to the syntheses of Schiff base, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide.

Yet another aspect of the invention comprises a method for the synthesis of  
5 antimycobacterial compounds comprising the formula:




wherein  $R_1$  is H or  $CH_3$ ; and

wherein  $R_2$  is  $C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

wherein  $R_1R_2 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

which comprises refluxing



20 with absolute ethanol to produce a solution and adding a carbonyl compound comprising the formula of:




wherein  $R_3 = H$  or  $CH_3$ ; and

wherein  $R_4 = C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

wherein  $R_3$  and  $R_4 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

to the solution to produce a reaction mixture. The reaction mixture is distilled and diethyl ether is added to the reaction mixture. The reaction mixture is then filtered and the resulting filtrate is then dried to produce I.

Yet another embodiment of the invention comprises a method for producing an antimycobacterial compound comprising the formula of:






wherein  $R_1$  = wherein  $R_1$  is H or  $CH_3$

5 wherein  $R_2 = C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

10 wherein  $R_1R_2 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

wherein  $R_3 = C_1$  or  $C_2$  alkyl

which comprises refluxing




15 wherein  $R_1$  is H or  $CH_3$ ; and

20 wherein  $R_2$  is  $C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

wherein  $R_1R_2 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;


25 with a carboxylic acid anhydride comprising the formula of:



wherein  $R = C_1$  or  $C_2$  alkyl


to produce a reaction mixture. The reaction mixture is dried and ether is added to the dried reaction mixture to form a solution. The ether is separated from the solution to yield an aqueous layer. The aqueous layer is extracted with ether and the resulting ether extracts are dried to produce **II**.

- 5 Another embodiment of the invention comprises a method for producing an antimycobacterial compound comprising the formula of:




10 wherein  $R_1 = C_1$  to  $C_6$  alkyl,  $C_2$  to  $C_6$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_{10}$  substituted alkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;

- 15 which comprises refluxing




with ethanol to produce a solution and adding an isothiocyanate comprised of the formula of:



wherein R = C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>10</sub> substituted alkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;


to the solution to form a reaction mixture. The reaction mixture is cooled and filtered to produce **III**.

Yet another aspect of the invention comprises a method for producing an antimycobacterial compound comprising the formula of:




wherein R<sub>1</sub> = C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>10</sub> substituted alkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;

which comprises adding diethyl ether to



(1)

to produce a solution. The solution is boiled and a carboxylic acid anhydride comprising the formula of:



wherein R= C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>10</sub> substituted alkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;

is added in ether to the solution to form a reaction mixture. The reaction mixture is refluxed and cooled to produce **IV**.

Another aspect of this invention involves pharmaceutical compositions comprised of formulas **I**, **II** and **III**.

The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formula **I**, **II** and **III** of this invention with a solid or liquid pharmaceutically acceptable carrier, and optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch,

gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water, water-propylene glycol, and water-polyethylene glycol systems, optionally containing conventional coloring agents, flavoring agents, stabilizers and thickening agents.

The pharmaceutical composition can be provided by employing conventional techniques. Preferably the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of Formula **I**, **II** and **III** according to this invention.

The quantity of active component, that is, the compounds of Formula **I**, **II** and **III** according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component can range between 20% to 80% by weight of the composition.

#### Brief Description of the Drawing(s)

Fig. 1 is bar graph depicting the lipophilicities of INH and isonicotinoylhydrazones of terephthalaldehyde, benzaldehyde, tetradecanal, citronellal and tridecanal.

Fig. 2 is a bar graph depicting the *in vivo* activity of compounds of the invention.

#### Description of the Preferred Embodiment(s)

A general procedure was developed to estimate the relative lipophilicities of compounds by observation of their partitioning between an aqueous solvent and water in biphasic liquid-liquid extraction. As depicted in Fig. 1, the ratio of amounts in each of the respective phases was

0569732-100000  
10  
obtained and compared to the ratio for INH as standard, *viz.*, ratio is set to unity. The compounds of the invention have been prepared with lipophilicities several orders of magnitude greater than that of INH. The advent of a quantitative method for lipophilicity determinations has been particularly important in the examination of the compounds disclosed herein. It is  
5 unexpected that the compounds of the invention, such as the Schiff bases and oxadiazolines, have increases in molecular weights by a factor of as much as 2 or more with respect to isoniazid and also have increases in lipophilicities of as much as several orders of magnitude. For example, among the oxadiazolines, where substituent groups R<sub>1</sub> or R<sub>2</sub> may be aromatics substituted with polarizing functional groups, measured lipophilicities are unexpectedly high. Thus, for the oxadiazoline in which R<sub>1</sub>=H and R<sub>2</sub>=3,4-difluorophenyl, the lipophilicity is some  
10 three orders of magnitude greater than that of INH, a result which is unexpected.

## Experimental Procedures

### General Methods and Materials

  
15

Elemental analyses were performed by Galbraith Laboratories, Knoxville, Tennessee. Melting points (mp) were taken in open capillary tubes using a Mel-Temp apparatus, measured in degrees Centigrade (°C) and are corrected. Infrared (IR) spectra were recorded on a Perkin-Elmer Model 1600 Fourier transform spectrophotometer as Nujol mulls and are reported in  
20 wavenumbers ( $\nu$ , cm<sup>-1</sup>). Except as specified in the individual procedures, reactants and reagents were obtained from Aldrich Chemical Company and were used as received. Proton nuclear magnetic resonance (NMR) spectra were taken on Bruker 200 or 300 Fourier transform instruments in dimethyl sulfoxide-d<sub>6</sub> and are reported in parts per million delta ( $\delta$ ) downfield from internal tetramethylsilane as reference. High resolution mass spectra (HRMS) and low  
25 resolution mass spectra were determined at the National Institutes of Health Mass Spectrometry

Facility at Michigan State University, East Lansing, Michigan. *Abbreviations:* Standard abbreviations are used for masses in grams (g); volumes in milliliters (mL); quantities in millimoles (mmol); magnetic resonance field strengths in megahertz (Mhz); relative signal strengths in proton NMR (H); proton NMR coupling constants (J) in cycles per second (cps);  
5 proton multiplicities as singlets (s), doublets (d), triplets (t) and multiplets (m).

#### Method for Obtaining Quantitative Estimates of Relative Lipophilicities

A general procedure was devised to estimate relative lipophilicities of the compounds of the invention by observation of their partitioning between an organic phase and water. Thus, to a  
10 weighed amount of compound (0.75 mmole) in a flat-bottomed Florence flask containing a stirring bar was delivered by pipet distilled water (5 mL) and also by pipet chloroform (5 mL). The flask was sealed with a cork and paraffin, and the contents were magnetically stirred vigorously for 30 minutes. The cork, paraffin and stirring bar were carefully removed, and the contents of the flask were transferred to a 60 mL separatory funnel. The layers were allowed to  
15 stand to achieve good separation. The layers were separated using the separatory funnel. Each layer was individually allowed to evaporate to dryness over night on a pre-weighed watchglass. The ratio of amounts of dry compound remaining after evaporation of the layers on the two watchglasses was obtained (chloroform to water). This ratio was then compared to the same ratio for isoniazid as standard, giving the estimate of relative lipophilicities. The lipophilicity  
20 comparison was expressed as

$[A_{\text{cmpd}}(\text{CHCl}_3)/A_{\text{cmpd}}(\text{H}_2\text{O}) : A_{\text{inh}}(\text{CHCl}_3)/A_{\text{inh}}(\text{H}_2\text{O})]$ , where

$A_{\text{cmpd}}(\text{solvent})$  refers to the amount of compound in chloroform or water, as appropriate and  $A_{\text{inh}}(\text{solvent})$  refers to the amount of isonicotinic acid hydrazide in chloroform or water, as appropriate.

Representative examples of the comparisons are provided in Figure 1 and in the following Chart.

Within the Chart, numbers refer to compounds derived from the individual examples of experimental procedures within each family.

5 **Chart.** *Quantitative Estimates of Relative Lipophilicities of the Compounds of the Invention*

Compound of Schiff Base Example (Relative Lipophilicity)

43 (200)

45 (45)

10 47 (316)

48 (566)

49 (433)

51 (400)

52 (189)

Compound of Oxadiazoline Example (Relative Lipophilicity)


4 (35,667)

8 (1333)

9 (1426)

20 10 (3080)

General Structural Outline for Schiff Base Synthesis



This section describes the general considerations for the synthesis of Schiff bases. The Schiff bases are prepared by the reactions of isonicotinic acid hydrazide with carbonyl



compounds in an appropriate solvent. Reaction conditions and solvent choices are critical to insure that the products of the syntheses are isolated in useful form.

The biological evaluation of compounds prepared for the purposes of drug design and drug discovery requires that materials be readily available in pure form on quantity scale, generally understood to be gram or multi-gram scale, as opposed to milligram scale. Gram scale quantities are necessary for the large numbers of biological tests which must be performed and replicated for the evaluation of a new drug candidate.

Products of synthetic reactions are most desirable when they can be easily and cheaply obtained as dry and free-flowing solids. In the long run, dry and free-flowing solids permit better formulations of drugs as tablets, capsules or syrups. The method of Schiff base synthesis disclosed herein yields products directly as dry free-flowing solids in analytically pure form. The prior art synthesis yields products that are obtained as intractable oils, difficult and labor-intensive to purify or bring into dry free-flowing form. The products of synthesis disclosed herein are suitable for biological evaluation or for further chemical transformation to other Schiff base congeners.

It is within the scope of the invention that the method of the Schiff base synthesis allows the economical use of solvents. The method of Schiff base synthesis conserves the use of solvents. The solvents, disclosed herein, which are required are inexpensive and may be conveniently recycled, if desired, by the use of a technique described below.

Isonicotinic acid hydrazide is used as received directly and inexpensively in greater than 95% purity from such commercial sources as Fluka A.-G., Lancaster or Aldrich Chemical Companies, all of which can supply this material in pure form in bulk quantities. Purity is confirmed by analysis using melting point, infrared, near infrared and magnetic resonance spectroscopy.

A 0.4 Molar solution is prepared of isonicotinic acid hydrazide in absolute ethanol, at reflux. The ethanol is used as received from Pharmco, Incorporated. The preparation of the solution at reflux is done by mixing the required weight of isonicotinic acid hydrazide with the necessary volume of absolute ethanol in a standard taper round bottom flask fitted for reflux with  
5 a temperature-controlled heating mantle, carborundum boiling chip and condenser. The volume of the flask is chosen in such a way that the contents of the entire reaction mixture do not exceed 50% of the flask's nominal capacity.

At room temperature, much of the isonicotinic acid hydrazide does not dissolve. The mixture of isonicotinic acid hydrazide and ethanol is brought to the boil and forms a clear  
10 colorless solution. The appearance of pronounced yellow color or pink tinge in the boiling mixture is unacceptable and generally indicates impure isonicotinic acid hydrazide. This impurity will lead to an unsatisfactory product from the viewpoint of quality and dry free-flowing form.

To the clear colorless solution at reflux is added dropwise through the top of the  
15 condenser the requisite carbonyl compound as a 5 Molar solution in absolute ethanol. The rate of addition is such that boiling does not cease during the addition. In the refluxing reaction mixture, the weights of carbonyl compound and isonicotinic acid hydrazide will have been chosen such that the compounds will be in a ratio by moles of about 1.67 to 1.00.

After the complete addition of the 5 Molar solution of the carbonyl compound, refluxing  
20 is continued for 1.5 hours. Heating is stopped and the clear colorless reaction mixture is allowed to cool and stand for 24 hours.

The condenser is removed from the round bottom flask, and the flask is fitted with a Dean-Stark apparatus to ensure convenient distillation and recovery of solvent for recycling. A new carborundum boiling chip is added, and the reaction mixture is brought to the boil. Ethanol

is distilled out of the reaction mixture using the Dean-Stark apparatus. The ethanol may thus be recovered and recycled for further use.

Removal of ethanol by distillation continues until the reaction mixture in the round bottom flask has been reduced to half volume. The reaction mixture is allowed to cool to room temperature and the round bottom flask is removed from the Dean-Stark apparatus.

The volume of the reaction mixture is noted. An equivalent volume of diethyl ether (EM Science absolute grade) is added. The mixture is swirled and permitted to stand. Solid begins to form in the solution and continues to form over night.

The solid is filtered off by gravity using Whatman No. 1 filter paper and allowed to dry on the filter cake. The dry free-flowing solid product thus obtained is then analyzed and characterized by the usual means, including melting point, infrared, near infrared, mass and magnetic resonance spectroscopy and elemental analysis.

#### Experimental Procedures – Schiff Bases

##### Example 1. Isonicotinoylhydrazone of Crotonaldehyde.

This compound was prepared from crotonaldehyde and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 73% of the isonicotinoylhydrazone of crotonaldehyde, melting point 198-201 °C; IR  $\nu$  3178, 1664, 1638, 1604, 1579, 1414, 1300, 1218, 1150, 1096, 1065, 1047, 998, 983, 930, 897, 847  $\text{cm}^{-1}$ ; NMR (300 megahertz)  $\delta$  11.8 (relative signal strength 1H, multiplicity singlet), 8.8 (2H, d, coupling constant  $J = 6$  cycles per second), 8.1 (1H, br d,  $J = 6$  cps), 7.8 (2H, d,  $J = 6$  cps), 6.25 (2H, m), 1.9 (3H, br d); high resolution mass spectrum (FAB method)  $m/z$  190.0983 ( $M + H$ ) ( $\text{C}_{10}\text{H}_{11}\text{N}_3\text{O} + H$  requires 190.0980) was obtained.

*Analysis.* Calculated for  $\text{C}_{10}\text{H}_{11}\text{N}_3\text{O}$ : C, 63.48; H, 5.86. Found: C, 63.79; H, 5.94.

#### Example 2. Isonicotinoylhydrazone of trans-2-Pentenal.

This compound was prepared from trans-2-pentenal and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 54% of the isonicotinoylhydrazone of trans-2-pentenal, melting point 161-164 °C; IR  $\nu$  3238, 1654, 1639, 1582, 1546, 1407, 1293, 1250, 1214, 1192, 1146, 1066, 1049, 1018, 1001, 957, 909, 840, 756, 722  $\text{cm}^{-1}$ ; NMR (300 megahertz)  $\delta$  11.8 (1H, br s), 8.8 (2H, d, J = 6 cps), 8.1 (1H, d, J = 6 cps), 7.8 (2H, d, J = 6 cps), 6.25 (2H, m), 2.3 (2H, m), 1.0 (3H, t, J = 6 cps); high resolution mass spectrum (FAB method) m/z 204.1139 (M + H) ( $\text{C}_{11}\text{H}_{13}\text{N}_3\text{O}$  + H requires 204.1137) was obtained.

*Analysis.* Calculated for  $\text{C}_{11}\text{H}_{13}\text{N}_3\text{O}$ : C, 65.01; H, 6.45. Found: C, 65.18; H, 6.42.

#### Example 3. Isonicotinoylhydrazone of trans-2-Hexenal.

From trans-2-hexenal, 30% of the isonicotinoylhydrazone of trans-2-hexenal, melting point 152-154 °C; IR  $\nu$  3224, 1654, 1639, 1596, 1582, 1546, 1406, 1300, 1212, 1191, 1152, 1067, 1041, 994, 956, 909, 838, 755, 722  $\text{cm}^{-1}$ ; NMR (300 megahertz)  $\delta$  11.8 (1H, br s), 8.8 (2H, d, J = 6 cps), 8.1 (1H, br d, J = 6 cps), 7.8 (2H, d, J = 6 cps), 6.25 (2H, m), 2.2 (2H, m), 1.45 (2H, sextet, J = 6 cps), 0.9 (3H, t, J = 6 cps); high resolution mass spectrum (FAB method) m/z 218.1284 (M + H) ( $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}$  + H requires 218.1293) was obtained .

*Analysis.* Calculated for  $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}$ : C, 66.34; H, 6.96. Found: C, 66.33; H, 7.13.

#### Example 4. Isonicotinoylhydrazone of trans-2-Heptenal.

From trans-2-heptenal, 35% of the isonicotinoylhydrazone of trans-2-heptenal, melting point 152-154 °C; IR  $\nu$  3246, 1656, 1633, 1595, 1582, 1546, 1420, 1407, 1331, 1297, 1236, 1213, 1148, 1068, 1034, 1006, 962, 939, 903, 876, 840, 754, 721  $\text{cm}^{-1}$ ; NMR (300 megahertz)  $\delta$

11.8 (1H, br s), 8.8 (2H, d, J = 6 cps), 8.1 (1H, br d, J = 6 cps), 7.8 (2H, d, J = 6 cps), 6.28 (2H, m), 2.2 (2H, m), 1.38 (4H, m), 0.9 (3H, t, J = 6 cps); high resolution mass spectrum (FAB method) m/z 232.1443 (M + H) ( $C_{13}H_{17}N_3O$  + H requires 232.1450) was obtained.

*Analysis.* Calculated for  $C_{13}H_{17}N_3O$ : C, 67.51; H, 7.41. Found: C, 67.38; H, 7.53.

5

Example 5. Isonicotinoylhydrazone of trans-2-Methyl-2-butenal.

From trans-2-methyl-2-butenal, 78% of the isonicotinoylhydrazone of trans-2-methyl-2-butenal, melting point 189-191°C; IR  $\nu$  3195, 1666, 1634, 1601, 1575, 1547, 1410, 1300, 1217, 1159, 1064, 1025, 996, 952, 848, 825, 724  $cm^{-1}$ ; NMR (300 megahertz)  $\delta$  11.7 (1H, br s), 8.8 (2H, d, J = 6 cps), 8.1 (1H, s), 7.8 (2H, d, J = 6 cps), 6.0 (1H, m), 1.9 (6H, m); high resolution mass spectrum (FAB method) m/z 204.1144 (M + H) ( $C_{11}H_{13}N_3O$  + H requires 204.1137) was obtained.

*Analysis.* Calculated for  $C_{11}H_{13}N_3O$ : C, 65.01; H, 6.45. Found: C, 65.04; H, 6.56.

Example 6. Isonicotinoylhydrazone of Citral.

This compound was prepared from citral and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 59% of the isonicotinoylhydrazone of citral, melting point 124-125°C; IR  $\nu$  3178, 3029, 1638, 1595, 1574, 1548, 1412, 1328, 1297, 1216, 1199, 1139, 1068, 1044, 989, 961, 907, 868, 849, 822, 761, 723  $cm^{-1}$  was obtained.

*Analysis.* Calculated for  $C_{16}H_{21}N_3O$ : C, 70.82; H, 7.80. Found: C, 70.78; H, 7.89.

Example 7. Di-isonicotinoylhydrazone of Glyoxal.

This compound was prepared from glyoxal and isonicotinic acid hydrazide (2 equivalents) using the General Structural Outline for Schiff Base Synthesis. 90% of the di-isonicotinoylhydrazone of glyoxal, melting point  $>305^{\circ}\text{C}$ ; IR  $\nu$  3198, 3052, 1666, 1579, 1535, 1407, 1310, 1288, 1213, 1156, 1063, 963, 915, 842, 763,  $730\text{ cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{14}\text{H}_{12}\text{N}_6\text{O}_2$ : C, 56.75; H, 4.08. Found: C, 56.85; H, 4.10.

#### Example 8. Isonicotinoylhydrazone of Ethyl Butyryl Acetate.

This compound was prepared from ethyl butyryl acetate and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 98% of the isonicotinoylhydrazone of ethyl butyryl acetate, melting point  $89\text{-}90^{\circ}\text{C}$ ; IR  $\nu$  3163, 1733, 1675, 1655, 1627, 1599, 1558, 1548, 1426, 1406, 1336, 1298, 1261, 1196, 1162, 1095, 1044, 1030, 992, 974, 918, 886, 842, 762,  $722\text{ cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_3$ : C, 60.64; H, 6.91. Found: C, 60.26; H, 7.02.

#### Example 9. Isonicotinoylhydrazone of Ethyl Acetoacetate.

This compound was prepared from ethyl acetoacetate and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 85% of the isonicotinoylhydrazone of ethyl acetoacetate, melting point  $99^{\circ}\text{C}$ ; IR  $\nu$  3200, 1733, 1690, 1655, 1635, 1598, 1554, 1535, 1406, 1336, 1301, 1268, 1182, 1142, 1067, 1037, 840, 756, 721,  $672\text{ cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_3$ : C, 57.82; H, 6.07. Found: C, 57.88; H, 6.26.

Example 10. Isonicotinoylhydrazone of Citronellal.

This compound was prepared from citronellal and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 29% of the isonicotinoylhydrazone of citronellal, melting point 78-80°C; IR  $\nu$  3226, 1651, 1619, 1596, 1544, 1410, 1297, 1215, 1135, 1067, 1032, 975, 906, 844, 757, 722  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{16}\text{H}_{23}\text{N}_3\text{O}$ : C, 70.30; H, 8.48. Found: C, 70.35; H, 8.78.

Example 11. Di-isonicotinoylhydrazone of Terephthalaldehyde.

This compound was prepared from terephthalaldehyde and isonicotinic acid hydrazide (2 equivalents) using the General Structural Outline for Schiff Base Synthesis. 90% of the di-isonicotinoylhydrazone of terephthalaldehyde, melting point >300°C; IR  $\nu$  3246, 3067, 1653, 1600, 1543, 1507, 1408, 1293, 1215, 1154, 1107, 1068, 969, 923, 839, 812, 755, 719  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{20}\text{H}_{16}\text{N}_6\text{O}_2$ : C, 64.51; H, 4.33. Found: C, 64.59; H, 4.44.

Example 12. Isonicotinoylhydrazone of 4-Butoxybenzaldehyde.

This compound was prepared from 4-butoxybenzaldehyde and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 91% of the isonicotinoylhydrazone of 4-butoxybenzaldehyde, melting point 148-149°C; IR  $\nu$  3272, 1650, 1260  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}_2$ : C, 68.68; H, 6.44. Found: C, 68.84; H, 6.61.

Example 13. Isonicotinoylhydrazone of Tridecanal.

This compound was prepared from tridecanal and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 73% of the isonicotinoylhydrazone of tridecanal, melting point 92-93°C; IR  $\nu$  3260, 3066, 1654, 1624, 1597, 1548, 1412, 1294, 1041, 846, 754, 727  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{19}\text{H}_{31}\text{N}_3\text{O}$ : C, 71.88; H, 9.84. Found: C, 71.68; H, 10.14.

#### Example 14. Isonicotinoylhydrazone of Perillaldehyde.

This compound was prepared from perillaldehyde and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 98% of the isonicotinoylhydrazone of perillaldehyde, melting point 86-88°C; IR  $\nu$  3464, 3192, 1667, 1636, 1604, 1585, 1562, 1532, 1410, 1290, 1235, 1185, 1140, 1062, 1042, 1006, 971, 942, 910, 888, 847, 754, 722  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{16}\text{H}_{19}\text{N}_3\text{O} \times 1.5 \text{ H}_2\text{O}$ : C, 64.84; H, 7.48. Found: C, 64.75; H, 7.60.

#### Example 15. Isonicotinoylhydrazone of 4-Nitrobenzaldehyde.

This compound was prepared from 4-nitrobenzaldehyde and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 96% of the isonicotinoylhydrazone of 4-nitrobenzaldehyde, melting point 279-280°C, lit mp 270-271°C [Shchukina et al., *Doklady Akad. Nauk S.S.S.R.*, 84, 981-984 (1952); *Chem. Abstr.*, 46, 10431 i (1952)], lit mp 273-274°C [Fenech et al., *Farmaco, Ed. Sci.*, 13, 681 (1958)] was obtained.



Example 16. Isonicotinoylhydrazone of Cyclohexanone.

This compound was prepared from cyclohexanone in 81% yield, mp 167-168 °C, lit mp 162-163 °C [Shchukina et al., *Doklady Akad. Nauk S.S.S.R.*, 84, 981-984 (1952); *Chem. Abstr.*, 46, 10431 i (1952)]; IR  $\nu$  3212, 1662, 1637, 1597, 1528, 1406, 1302, 1285, 1245, 1214, 1139, 1036, 839, 755, 722  $\text{cm}^{-1}$ ; NMR (300 megahertz)  $\delta$  10.8 (1H, br s), 8.7 (2H, d, J = 6 cps), 7.6 (2H, d, J = 6 cps), 2.4 (4H, m), 1.6 (4H, m).

*Analysis.* Calculated for  $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}$ : C, 66.32; H, 6.97. Found: C, 65.90; H, 6.90.

This material was further characterized by its exchange reaction with benzaldehyde to produce the isonicotinoylhydrazone of benzaldehyde, in a procedure devised for this application.

Thus the isonicotinoylhydrazone of cyclohexanone (0.82 g) was weighed into a 50 mL pear-shaped flask and brought to reflux with absolute ethanol (15 mL). To this mixture was added benzaldehyde (0.69 g) at such a rate that vigorous boiling continued throughout the addition. The aldehyde was washed in with a further portion of ethanol (3 mL), all at the boil. Refluxing was continued for one hour. The mixture was allowed to cool to room temperature and ether (35 mL) added. Over night a solid formed (90%), which was identical (band-for-band comparison of infrared spectra) to an authentic specimen of the isonicotinoylhydrazone of benzaldehyde, independently prepared from isonicotinic acid hydrazide and benzaldehyde according to the procedure specified for Example 18.

Example 17. Isonicotinoylhydrazone of Acetone.

This compound was prepared from acetone and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 48% of the isonicotinoylhydrazone of acetone, melting point 161-162 °C; IR  $\nu$  3184, 1654, 1633, 1534, 1297, 1266, 1208, 1148, 1062,

1028, 989, 914, 836  $\text{cm}^{-1}$ ; NMR (300 megahertz)  $\delta$  10.8 (1H, br s), 8.7 (2H, d,  $J = 6$  cps), 7.7 (2H, d,  $J = 6$  cps), 2.0 (3H, s), 1.9 (3H, s).

*Analysis.* Calculated for  $\text{C}_9\text{H}_{11}\text{N}_3\text{O}$ : C, 61.00; H, 6.25. Found: C, 60.95; H, 6.21.

This material was further characterized by its exchange reaction with 2,4-dinitrophenylhydrazine to produce the 2,4-dinitrophenylhydrazone of acetone, in a reaction procedure devised as part of this work. Thus the isonicotinoylhydrazone of acetone (0.135 g) was dissolved in the minimum volume (5 mL) of absolute ethanol in a 50 mL conical flask. To this solution was then added standard 2,4-dinitrophenylhydrazine reagent (10 mL, prepared according to A. Vogel, *Text-book of Practical Organic Chemistry*, 1966, p. 1061) at room temperature. Formation of a yellow precipitate was instantaneous. The mixture was warmed on a hot plate to just below the boiling point and swirled continuously. The mixture was then cooled by holding the outside of the reaction flask in a stream of cold tap water. The resulting yellow-orange 2,4-dinitrophenylhydrazone of acetone (72%) was allowed to stand for a few hours, then filtered off by gravity, mp 127-128  $^{\circ}\text{C}$  (from ethanol); mixed mp with an authentic specimen (prepared directly from acetone and 2,4-dinitrophenylhydrazine according to the method of Vogel cited above) 127-128  $^{\circ}\text{C}$ ; lit mp 128  $^{\circ}\text{C}$  [A. Vogel, *Text-book of Practical Organic Chemistry*, 1966, pp. 334, 346, 723, 743; Behforouz, et al., *J. Org. Chem.*, 50, 1186 (1985)].

#### Example 18. Isonicotinoylhydrazone of Benzaldehyde.

This compound was prepared from benzaldehyde and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 98% of the isonicotinoylhydrazone of benzaldehyde, melting point 197 $^{\circ}\text{C}$ , lit mp 194-195  $^{\circ}\text{C}$  [P. Stecher, editor, *The Merck Index*, Rahway, New Jersey, Merck and Company, 1968, p. 587 and Fenech et al., *Farmaco, Ed. Sci.*,

13, 681 (1958)]; IR  $\nu$  3192, 1691, 1598, 1565, 1412, 1354, 1284, 1150, 1081, 1058, 998, 952, 920, 845, 767, 724  $\text{cm}^{-1}$ .

This material was further characterized by its exchange reaction with 2,4-dinitrophenylhydrazine to produce the 2,4-dinitrophenylhydrazone of benzaldehyde, in a reaction procedure devised as part of this work. Thus the isonicotinoylhydrazone of benzaldehyde (0.153 g) was dissolved with warming in the minimum volume (*ca.* 5 mL) of absolute ethanol in a 50 mL conical flask. To this solution was then added standard 2,4-dinitrophenylhydrazine reagent (10 mL, prepared according to A. Vogel, *Text-book of Practical Organic Chemistry*, 1966, p. 1061) at room temperature. Formation of a fluorescent yellow-orange precipitate was immediate. The resulting yellow-orange 2,4-dinitrophenylhydrazone of benzaldehyde (91%) was filtered off by gravity, mp 231-234 °C, lit mp 237 °C [A. Vogel, *Text-book of Practical Organic Chemistry*, 1966, pp. 334, 346, 723, 743; Behforouz et al., *J. Org. Chem.*, 50, 1186 (1985)].

#### Example 19. Isonicotinoylhydrazone of Salicylaldehyde.

This compound was prepared from salicylaldehyde and isonicotinic acid hydrazide, obtaining 83% of the isonicotinoylhydrazone of salicylaldehyde, melting point 247-250 °C, lit mp 232-233 °C and 251 °C [P. Stecher, editor, *The Merck Index*, Rahway, New Jersey, Merck and Company, 1968, p. 587], lit mp 238-239 °C [Shchukina et al., *Doklady Akad. Nauk S.S.S.R.*, 84, 981-984 (1952); *Chem. Abstr.*, 46, 10431 i (1952)], lit mp 251 °C [Buu-Hoi et al., *J. Chem. Soc.*, 1358 (1953)], lit mp 243-245 °C [Fenech et al., *Farmaco, Ed. Sci.*, 13, 681 (1958)], lit mp 243 °C [Penkert, *Arzneimittel Forsch.*, 7, 304 (1957)]; IR  $\nu$  3180, 1682, 1624, 1611, 1567, 1553, 1408, 1290, 1274, 1233, 1208, 1159, 1067, 1034, 999, 872, 850, 772, 752, 688  $\text{cm}^{-1}$ .

This material was further characterized by its exchange reaction with 2,4-dinitrophenylhydrazine to produce the 2,4-dinitrophenylhydrazone of salicylaldehyde, in a reaction procedure devised as part of this work. Thus the isonicotinoylhydrazone of salicylaldehyde (0.150 g) was mixed with warming with 5 mL of absolute ethanol in a 50 mL conical flask. Not all the solid dissolved. The fluid portion of the mixture was drawn off with a Pasteur pipet and added directly to standard 2,4-dinitrophenylhydrazine reagent (10 mL, prepared according to A. Vogel, *Text-book of Practical Organic Chemistry*, 1966, p. 1061) at room temperature. Formation of a fluorescent orange precipitate was immediate. The resulting orange 2,4-dinitrophenylhydrazone of salicylaldehyde (17%) was filtered off by gravity, mp 248-250 °C, lit mp 252°C [A. Vogel, *Text-book of Practical Organic Chemistry*, 1966, pp. 334, 346, 723, 743; Behforouz et al., *J. Org. Chem.*, 50, 1186 (1985)].

Example 20. Isonicotinoylhydrazone of Vanillin.

This compound was prepared from vanillin and isonicotinic acid hydrazide, yielding 92% of the isonicotinoylhydrazone of vanillin, melting point 226-227°C, lit mp 219-220°C [Shchukina et al., *Doklady Akad. Nauk S.S.S.R.*, 84, 981-984 (1952); *Chem. Abstr.*, 46, 10431 i (1952)]; IR  $\nu$  3190, 1651  $\text{cm}^{-1}$ .

Example 21. Isonicotinoylhydrazone of para-Anisaldehyde.

This compound was prepared from para-anisaldehyde and isonicotinic acid hydrazide using the General Structural Outline for Schiff Base Synthesis. 92% of the isonicotinoylhydrazone of para-anisaldehyde, melting point 137-139°C, lit mp 126-127°C [Shchukina et al., *Doklady Akad. Nauk S.S.S.R.*, 84, 981-984 (1952); *Chem. Abstr.*, 46, 10431 i (1952)], lit mp 172-174°C [Fox et al., *J. Org. Chem.*, 18, 983 (1953)]; IR  $\nu$  3436, 1655  $\text{cm}^{-1}$ ;

NMR (200 megahertz)  $\delta$  12.0 (1H, br s), 8.8 (2H, d, J = 6 cps), 8.4 (1H, s), 7.8 (2H, d, J = 6 cps), 7.7 (2H, d, J = 6 cps), 7.0 (2H, d, J = 6 cps), 3.9 (3H, s).

This material was further characterized by its qualitative exchange reaction with 2,4-dinitrophenylhydrazine to produce the 2,4-dinitrophenylhydrazone of para-anisaldehyde, in a reaction procedure devised as part of this work. Thus the isonicotinoylhydrazone of para-anisaldehyde (0.250 g) was dissolved in the minimum volume (5 mL) of absolute ethanol in a 50 mL conical flask. The material dissolved readily without heating. To this solution was then added standard 2,4-dinitrophenylhydrazine reagent (10 mL, prepared according to A. Vogel, *Text-book of Practical Organic Chemistry*, New York, John Wiley and Sons, 1966, p. 1061) at room temperature. Formation of a bright orange precipitate was immediate. The resulting orange 2,4-dinitrophenylhydrazone of para-anisaldehyde was allowed to stand for a few hours, then filtered off by gravity, mp 249-252 °C (from ethanol); lit mp 252 °C [A. Vogel, *Text-book of Practical Organic Chemistry*, New York, John Wiley and Sons, 1966, pp. 334, 346, 723, 743; see also M. Behforouz, J. Bolan and M. Flynt, *J. Org. Chem.*, 50, 1186 (1985)].

#### Example 22. Isonicotinoylhydrazone of meta-Anisaldehyde.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 90% yield of the isonicotinoylhydrazone of meta-anisaldehyde, mp 199 °C; IR  $\nu$  3195, 1643  $\text{cm}^{-1}$ ; NMR (200 megahertz)  $\delta$  12.1 (1H, br s), 8.9 (2H, d, J = 6 cps), 8.4 (1H, s), 7.8 (2H, d, J = 6 cps), 7.4-7.0 (3H, m), 3.9 (3H, s) was obtained.

#### Example 23. Isonicotinoylhydrazone of Methyl Jasmonate.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 67% yield of the isonicotinoylhydrazone of methyl jasmonate, mp 90-91 °C; IR  $\nu$

3271, 1740, 1664, 1644, 1554, 1527, 1403, 1300, 1283, 1264, 1201, 1158, 1126, 1061, 1036, 840, 754, 722  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}_3 \times \text{H}_2\text{O}$ : C, 63.94; H, 7.48. Found: C, 64.30; H, 7.07.

5

Example 24. Isonicotinoylhydrazone of Decanal.

This compound was prepared from isonicotinic acid hydrazide and decyl aldehyde, giving a 93% yield of the isonicotinoylhydrazone of decanal, mp 83-85°C; IR  $\nu$  3252, 1655, 1624, 1597, 1548, 1411, 1324, 1297, 1248, 1220, 1158, 1066, 1036, 964, 935, 891, 876, 846, 754, 728  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{16}\text{H}_{25}\text{N}_3\text{O}$ : C, 69.78; H, 9.15. Found: C, 69.82; H, 9.67.

Example 25. Isonicotinoylhydrazone of Tetradecanal.

This compound was prepared from isonicotinic acid hydrazide and tetradecanal, giving a 73% yield of the isonicotinoylhydrazone of tetradecanal, mp 89-91°C; IR  $\nu$  3258, 1654, 1624, 1553, 1410, 1295, 1221, 1158, 1120, 1099, 1065, 1042, 962, 846, 753, 718  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{20}\text{H}_{33}\text{N}_3\text{O}$ : C, 72.46; H, 10.04. Found: C, 72.20; H, 10.33.

Example 26. Isonicotinoylhydrazone of ortho-Anisaldehyde.

This compound was prepared from isonicotinic acid hydrazide and ortho-anisaldehyde, giving a 78% yield of the isonicotinoylhydrazone of ortho-anisaldehyde, mp 194-195°C, lit mp 219-220°C [H. Fujiwara, *Yakugaku Zasshi*, 78, 1034 (1958) and 1045 (1958)]; IR  $\nu$  3191, 1652, 1602, 1578, 1558, 1551, 1439, 1406, 1304, 1256, 1163, 1064, 1045, 1024, 961, 929, 851, 836, 753, 686  $\text{cm}^{-1}$ .

Example 27. Isonicotinoylhydrazone of trans-alpha-Methylcinnamaldehyde.

This compound was prepared from isonicotinic acid hydrazide and trans-alpha-methylcinnamaldehyde, giving a 76% yield of the isonicotinoylhydrazone of trans-alpha-methylcinnamaldehyde as a sticky solid; IR  $\nu$  3187, 1651, 1622, 1598, 1579, 1551, 1404, 1309, 1212, 1075, 1016, 967, 935, 841, 749, 723, 697  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}$ : C, 72.43; H, 5.70. Found: C, 72.19; H, 5.67.

Example 28. Isonicotinoylhydrazone of 4-Fluorobenzaldehyde.

This compound was prepared from isonicotinic acid hydrazide and 4-fluorobenzaldehyde according to the General Structural Outline for Schiff Base Synthesis, giving a 76% yield of the isonicotinoylhydrazone of 4-fluorobenzaldehyde as a white solid, mp 187-189 °C; IR  $\nu$  3469, 3257, 1656, 1599, 1562, 1551, 1509, 1408, 1302, 1232, 1156, 1064, 1003, 840, 789, 752  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{10}\text{N}_3\text{OF} \times \text{H}_2\text{O}$ : C, 59.76; H, 4.63. Found: C, 59.68; H, 4.68.

Example 29. Isonicotinoylhydrazone of Cyclopentanone.

This compound was prepared from isonicotinic acid hydrazide and cyclopentanone according to the General Structural Outline for Schiff Base Synthesis, giving a 53% yield of the isonicotinoylhydrazone of cyclopentanone as a white solid, mp 177 °C, IR  $\nu$  3197, 1655, 1596, 1534, 1414, 1405, 1291, 1210, 1168, 1140, 1064, 1041, 992, 925, 840, 762, 754, 722  $\text{cm}^{-1}$ .

This material was characterized on the basis of its exchange reaction with benzaldehyde to produce the isonicotinoylhydrazone of benzaldehyde, in a procedure devised for this application. Thus the isonicotinoylhydrazone of cyclopentanone (0.73 g) was weighed into a 50

mL pear-shaped flask and brought to reflux with absolute ethanol (12 mL). To this mixture was added benzaldehyde (0.64 g) at such a rate that vigorous boiling continued throughout the addition. The aldehyde was washed in with a further portion of ethanol (3 mL), all at the boil. Refluxing was continued for one hour. The mixture was allowed to cool to room temperature and ether (35 mL) added. Over night a solid formed (48%), which was identical (band-for-band comparison of infrared spectra) to an authentic specimen of the isonicotinoylhydrazone of benzaldehyde, independently prepared from isonicotinic acid hydrazide and benzaldehyde according to the procedure specified for Example 18.

Example 30. Isonicotinoylhydrazone of 4-tertiary-Butylcyclohexanone.

This compound was prepared from isonicotinic acid hydrazide and 4-tertiary-butylcyclohexanone according to the General Structural Outline for Schiff Base Synthesis, giving a 82% yield of the isonicotinoylhydrazone of tertiary-butylcyclohexanone as a white solid, mp 152 °C, IR  $\nu$  3197, 1655, 1596, 1534, 1414, 1405, 1291, 1210, 1168, 1140, 1064, 1041, 992, 925, 840, 762, 754, 722  $\text{cm}^{-1}$ .

Example 31. Isonicotinoylhydrazone of Cycloheptanone.

This compound was prepared from isonicotinic acid hydrazide and cycloheptanone according to the General Structural Outline for Schiff Base Synthesis, giving a 60% yield of the isonicotinoylhydrazone of cycloheptanone as a white solid, mp 123 °C, IR  $\nu$  3197, 1655, 1596, 1534, 1414, 1405, 1291, 1210, 1168, 1140, 1064, 1041, 992, 925, 840, 762, 754, 722  $\text{cm}^{-1}$ .

Example 32. Di-isonicotinoylhydrazone of 1,4-Cyclohexanedione.



This compound was prepared from isonicotinic acid hydrazide (2 equivalents) and 1,4-cyclohexanedione according to the General Structural Outline for Schiff Base Synthesis, giving a 99% yield of the di-isonicotinoylhydrazone of 1,4-cyclohexanedione as a white solid, mp 177°C (dec), IR  $\nu$  3262, 1714, 1649, 1633, 1596, 1552, 1520, 1492, 1416, 1306, 1292, 1281, 1215, 1142, 1070, 1043, 992, 842, 756, 726  $\text{cm}^{-1}$ .

Example 33. Isonicotinoylhydrazone of 3,3,5-Trimethylcyclohexanone.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. One thus obtained a 76% yield of the isonicotinoylhydrazone of 3,3,5-trimethylcyclohexanone, mp 149-151 °C; IR  $\nu$  3174, 1650, 1628, 1598, 1552, 1533, 1409, 1339, 1293, 1227, 1164, 1139, 1068, 1032, 842, 760, 722  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{15}\text{H}_{21}\text{N}_3\text{O}$ : C, 69.47; H, 8.16. Found: C, 69.42; H, 8.17.

Example 34. Isonicotinoylhydrazone of 2-Fluoro-4-Methoxybenzaldehyde.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 70% yield of the isonicotinoylhydrazone of 2-fluoro-4-methoxybenzaldehyde, mp, 128-132 °C (uncorr); IR  $\nu$  3452, 3150, 1657, 1622, 1598, 1592, 1549, 1505, 1412, 1333, 1260, 1248, 1224, 1198, 1154, 1053, 1023, 960, 937, 919, 838, 728, 725  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{14}\text{H}_{12}\text{N}_3\text{O}_2\text{F} \times \text{H}_2\text{O}$ : C, 57.73; H, 4.84. Found: C, 57.56; H, 4.90.

Example 35. Isonicotinoylhydrazone of 6-Methoxy-2-naphthaldehyde.

This compound was prepared in 93% yield from the reaction of isonicotinic acid hydrazide and 6-methoxy-2-naphthaldehyde, mp 198-199 °C (uncorr), IR  $\nu$  3213, 1658, 1625, 1594, 1550, 1408, 1295, 1273, 1248, 1196, 1187, 1144, 1051, 1030, 958, 941, 867, 844, 813, 749, 720  $\text{cm}^{-1}$ .

Example 36. Isonicotinoylhydrazone of 3-Methoxy-4,5-methylenedioxybenzaldehyde.

This compound was prepared in 76% yield from the reaction of isonicotinic acid hydrazide and 3-methoxy-4,5-methylenedioxybenzaldehyde, mp 190-191°C (uncorr), IR v 3203, 1652, 1590, 1546, 1505, 1406, 1313, 1299, 1200, 1166, 1133, 1091, 1064, 1039, 992, 950, 926, 907, 842, 823, 753, 738, 721 cm<sup>-1</sup>.

Example 37. Isonicotinoylhydrazone 4-methoxy-1-naphthaldehyde.

This compound was prepared in 89% yield from the reaction of isonicotinic acid hydrazide and 4-methoxy-1-naphthaldehyde, mp 238-239°C (uncorr), IR v 3172, 1677, 1603, 1573, 1555, 1510, 1407, 1322, 1294, 1246, 1227, 1173, 1147, 1092, 1066, 1049, 1029, 995, 979, 951, 928, 905, 840, 766, 709 cm<sup>-1</sup>.

Example 38. Isonicotinoylhydrazone 2-Naphthaldehyde.

This compound was prepared in 94% yield from the reaction of isonicotinic acid hydrazide and 2-naphthaldehyde, mp 176-177°C (uncorr), IR v 3185, 1669, 1652, 1568, 1558, 1419, 1335, 1293, 1180, 1141, 1075, 1064, 998, 934, 955, 922, 896, 883, 863, 847, 835, 753, 740, 721 cm<sup>-1</sup>.

Example 39. Isonicotinoylhydrazone 2-Methoxy-1-Naphthaldehyde.

This compound was prepared in 71% yield from the reaction of isonicotinic acid hydrazide and 2-methoxy-1-naphthaldehyde, mp 202-203°C (uncorr), IR v 3181, 1646, 1623, 1584, 1546, 1508, 1404, 1339, 1289, 1272, 1250, 1184, 1150, 1084, 1067, 1041, 1023, 991, 961, 934, 908, 862, 838, 807, 778, 752, 744, 705 cm<sup>-1</sup>.

Example 40. Isonicotinoylhydrazone 1-Naphthaldehyde.

This compound was prepared in 83% yield from the reaction of isonicotinic acid hydrazide and 1-naphthaldehyde, mp 208-209°C (uncorr), IR  $\nu$  3174, 1676, 1599, 1573, 1541, 1507, 1408, 1338, 1281, 1211, 1176, 1146, 1089, 1074, 1059, 1016, 996, 942, 914, 848, 804, 777, 744, 703  $\text{cm}^{-1}$ .

Example 41. Isonicotinoylhydrazone of 2-Chlorobenzaldehyde. This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 66% yield of the

isonicotinoylhydrazone of 2-chlorobenzaldehyde, mp 218-221 °C; IR  $\nu$  3150, 1673, 1600, 1552, 1517, 1494, 1412, 1341, 1322, 1282, 1217, 1157, 1131, 1068, 1047, 1027, 1002, 958, 926, 876, 842, 765, 732, 713  $\text{cm}^{-1}$ ; NMR (300 Mhz)  $\delta$  12.3 (1H, br s), 8.9 (1H, s), 8.8 (2H, d, J = 6 cps), 8.1 (1H, m), 7.9 (2H, d, J = 6 cps), 7.4-7.6 (3H, m) was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{10}\text{N}_3\text{OCl}$ : C, 60.13; H, 3.88. Found: C, 60.11; H, 3.86.

Example 42. Isonicotinoylhydrazone of 4-Bromobenzaldehyde. With 4-bromobenzaldehyde,

one obtained a 91% yield of the isonicotinoylhydrazone of 4-bromobenzaldehyde, mp 218-219 °C; IR  $\nu$  3253, 3080, 1657, 1604, 1589, 1552, 1402, 1290, 1217, 1152, 1108, 1067, 1006, 962, 924, 852, 841, 822, 750, 711  $\text{cm}^{-1}$ ; NMR (300 Mhz)  $\delta$  12.2 (1H, br s), 8.8 (2H, d, J = 6 cps), 8.4 (1H, s), 7.8 (2H, d, J = 6 cps), 7.7-7.6 (4H, aromatic pseudo-quartet).

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{10}\text{N}_3\text{OBr}$ : C, 51.34; H, 3.31. Found: C, 51.32; H, 3.30.

Example 43. Isonicotinoylhydrazone of 3-Nitrobenzaldehyde.

With 3-nitrobenzaldehyde, one obtained an 85% yield of the isonicotinoylhydrazone of 3-nitrobenzaldehyde, mp 225 °C (uncorr); IR  $\nu$  3232, 1691, 1609, 1600, 1548, 1524, 1412, 1352, 1314, 1271, 1141, 1101, 1062, 996, 961, 948, 887, 843, 827, 815, 750, 739, 710  $\text{cm}^{-1}$ .

5      *Analysis.* Calculated for  $\text{C}_{13}\text{H}_{10}\text{N}_4\text{O}_3$ : C, 57.78; H, 3.73. Found: C, 57.69; H, 3.77.

Example 44. Isonicotinoylhydrazone of 4-Hexyloxybenzaldehyde.

With 4-hexyloxybenzaldehyde, an 87% yield of the isonicotinoylhydrazone of 4-hexyloxybenzaldehyde, mp 135-138°C; IR  $\nu$  3234, 3062, 1650, 1608, 1572, 1549, 1513, 1415, 1398, 1297, 1240, 1179, 1154, 1127, 1112, 1070, 1032, 993, 976, 961, 941, 922, 863, 846, 832, 810, 752, 725  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{19}\text{H}_{23}\text{N}_3\text{O}_2$ : C, 70.06; H, 7.07. Found: C, 70.07; H, 7.07.

Example 45. Isonicotinoylhydrazone of 2-Chloro-5-nitrobenzaldehyde.

With 2-chloro-5-nitrobenzaldehyde, the General Structural Outline for Schiff Base Synthesis was used to get a quantitative yield of the isonicotinoylhydrazone of 2-chloro-5-nitrobenzaldehyde, mp 239°C (uncorr); IR  $\nu$  3356, 3102, 1690, 1608, 1574, 1536, 1395, 1352, 1303, 1248, 1186, 1094, 1058, 1003, 938, 916, 846, 818, 738, 637  $\text{cm}^{-1}$ .

15      *Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_4\text{O}_3\text{Cl} \times 0.5\text{H}_2\text{O}$ : C, 49.77; H, 3.21. Found: C, 50.02;  
20      H, 3.09.

Example 46. Isonicotinoylhydrazone of 4-Chloro-3-nitrobenzaldehyde.

With 4-chloro-3-nitrobenzaldehyde, the General Structural Outline for Schiff Base Synthesis to get a quantitative yield of the isonicotinoylhydrazone of 4-chloro-3-

nitrobenzaldehyde, mp 231°C (uncorr); IR  $\nu$  3189, 1685, 1599, 1558, 1530, 1412, 1351, 1277, 1252, 1214, 1154, 1125, 1074, 1061, 1049, 998, 962, 942, 896, 846, 823, 748, 721  $\text{cm}^{-1}$  was used.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_4\text{O}_3\text{Cl}$ : C, 51.25; H, 2.98. Found: C, 51.20; H, 2.90.

5

Example 47. Isonicotinoylhydrazone of 2-Nitrobenzaldehyde.

With 2-nitrobenzaldehyde, a 97% yield of the isonicotinoylhydrazone of 2-nitrobenzaldehyde, mp 230 °C (uncorr); IR  $\nu$  3188, 1678, 1602, 1556, 1515, 1413, 1315, 1287, 1273, 1214, 1149, 1139, 1062, 998, 964, 932, 920, 880, 856, 848, 836, 788, 744  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{10}\text{N}_4\text{O}_3$ : C, 57.78; H, 3.73. Found: C, 57.51; H, 3.65.

Example 48. Isonicotinoylhydrazone of 2,6-Dichlorobenzaldehyde.

With 2,6-dichlorobenzaldehyde, 97% yield of the isonicotinoylhydrazone of 2,6-dichlorobenzaldehyde as an oily solid; IR  $\nu$  3150, 1681, 1605, 1592, 1555, 1416, 1354, 1274, 1222, 1192, 1148, 1000, 925, 842, 791, 778, 752, 720  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_3\text{OCl}_2$ : C, 53.08; H, 3.08. Found: C, 53.28; H, 3.21.

Example 49. Isonicotinoylhydrazone of 2,3-Dichlorobenzaldehyde.

With 2,3-dichlorobenzaldehyde, a 98% yield of the isonicotinoylhydrazone of 2,3-dichlorobenzaldehyde mp 227 °C (uncorr); IR  $\nu$  3188, 1687, 1602, 1585, 1547, 1497, 1411, 1350, 1278, 1248, 1214, 1189, 1155, 1141, 1096, 1060, 1042, 997, 972, 940, 848, 783, 742, 708  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_3\text{OCl}_2$ : C, 53.08; H, 3.08. Found: C, 53.16; H, 3.20.

Example 50. Isonicotinoylhydrazone of Acetophenone.

With acetophenone, 92% yield of the isonicotinoylhydrazone of acetophenone mp 169-170 °C; IR  $\nu$  3173, 1652, 1599, 1540, 1288, 1150, 1103, 975, 835, 757, 722  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{14}\text{H}_{13}\text{N}_3\text{O}$ : C, 70.27; H, 5.48. Found: C, 70.18; H, 5.51.

Example 51. Isonicotinoylhydrazone of 3,4-Difluorobenzaldehyde.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 86% yield of the isonicotinoylhydrazone of 3,4-difluorobenzaldehyde, mp 195-196 °C; IR  $\nu$  3167, 1677, 1624, 1598, 1552, 1523, 1507, 1341, 1301, 1265, 1150, 1109, 960, 942, 866, 817, 777, 753, 721, 712  $\text{cm}^{-1}$ ; NMR (300 Mhz)  $\delta$  12.2 (1H, s, vanished upon addition of  $\text{D}_2\text{O}$ ), 8.8 (2H, d,  $J = 6$  cps), 8.5 (1H, s), 7.8-7.4 (5H, m, including emergent 7.8 d,  $J = 6$  cps) was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_3\text{OF}_2$ : C, 59.77; H, 3.47. Found: C, 59.64; H, 3.46.

Example 52. Isonicotinoylhydrazone of 2,6-Difluorobenzaldehyde.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. A quantitative yield of the isonicotinoylhydrazone of 2,6-difluorobenzaldehyde, mp 239 °C (uncorr); IR  $\nu$  3161, 1654, 1624, 1608, 1569, 1550, 1412, 1305, 1238, 1154, 1076, 1066, 1000, 960, 926, 840, 782, 758, 728  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_3\text{OF}_2$ : C, 59.77; H, 3.47. Found: C, 59.92; H, 3.70.

Example 53. Isonicotinoylhydrazone of 3,4-Dichlorobenzaldehyde.

With 3,4-dichlorobenzaldehyde, an 88% yield of the isonicotinoylhydrazone of 3,4-dichlorobenzaldehyde mp 241-244 °C (uncorr); IR  $\nu$  3178, 1682, 1590, 1552, 1413, 1352, 1278, 1215, 1147, 1121, 1078, 1062, 1028, 999, 952, 937, 886, 846, 813, 747, 722  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_9\text{N}_3\text{OCl}_2$ : C, 53.08; H, 3.08. Found: C, 52.85; H, 3.20.

5

Example 54. Isonicotinoylhydrazone of 4-Chlorobenzaldehyde. This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 94% yield of the isonicotinoylhydrazone of 4-chlorobenzaldehyde, mp 215-216 °C; IR  $\nu$  3167, 1660, 1611, 1597, 1412, 1219, 1158, 1118, 1087, 1012, 952, 1000, 879, 838, 818, 751, 722  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{10}\text{N}_3\text{OCl}$ : C, 60.13; H, 3.88. Found: C, 60.05; H, 3.89.

Example 55. Isonicotinoylhydrazone of Ethyl 2-Oxo-4-phenylbutyrate.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 90% yield of the isonicotinoylhydrazone of ethyl 2-oxo4-phenylbutyrate, mp 104 °C; IR  $\nu$  3251, 1702, 1685, 1592, 1554, 1511, 1417, 1403, 1301, 1246, 1213, 1143, 1112, 1074, 1022, 994, 942, 875, 843, 798, 764, 754, 721, 706  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{18}\text{H}_{19}\text{N}_3\text{O}_3$ : C, 66.45; H, 5.89. Found: C, 66.10; H, 5.96.

Example 56. Isonicotinoylhydrazone of beta-Phenylcinnamaldehyde.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 86% yield of the isonicotinoylhydrazone of beta-phenylcinnamaldehyde, mp 223 °C; IR  $\nu$  3187, 1649, 1604, 1564, 1546, 1523, 1403, 1344, 1298, 1284, 1208, 1155, 1133, 1075, 1062, 1016, 992, 935, 916, 891, 880, 842, 771, 758, 745, 720  $\text{cm}^{-1}$  was obtained.

*Analysis.* Calculated for  $\text{C}_{21}\text{H}_{17}\text{N}_3\text{O}$ : C, 77.04; H, 5.23. Found: C, 76.78; H, 5.36.

Example 57. Isonicotinoylhydrazone of Di-2-Pyridyl Ketone.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 83% yield of the isonicotinoylhydrazone of di-2-pyridyl ketone, mp 150°C; IR  $\nu$  3363, 1699, 1583, 1513, 1432, 1320, 1283, 1263, 1224, 1135, 1112, 1093, 1077, 1054, 994, 970, 946, 905, 897, 842, 806, 789, 742  $\text{cm}^{-1}$  was obtained.


*Analysis.* Calculated for  $\text{C}_{17}\text{H}_{13}\text{N}_5\text{O} \times 2\text{H}_2\text{O}$ : C, 60.17; H, 5.04. Found: C, 60.11; H, 5.04.

Example 59. Isonicotinoylhydrazone of 2,4-Pentanedione.

This compound was prepared using the General Structural Outline for Schiff Base Synthesis. 85% yield of the monoisonicotinoylhydrazone of 2,4-pentanedione, mp 136°C, lit mp 131-133 °C [Yale et al., *Journal of Organic Chemistry*, 75, 1933 (1953)]; IR  $\nu$  3150, 1622, 1597, 1545, 1329, 1245, 1229, 1205, 1141, 1112, 1065, 1021, 1003, 971, 870, 840, 755, 736, 703  $\text{cm}^{-1}$  was obtained.

General Structural Outline for Diacylhydrazine Synthesis

A. Acylation Procedure.





Diacylhydrazine compounds are prepared by the reaction of isonicotinic acid hydrazide with carboxylic acid anhydrides. Reaction conditions and work-up methods are critical to insure that the products of the syntheses are obtained in acceptable form. Further, solvent choice and reaction times are critical to insure formation of the diacylhydrazine, preventing over-acylation.

5 Isonicotinic acid hydrazide (Fluka A.-G., Lancaster or Aldrich Chemical Companies) is weighed into a round bottom flask fitted for reflux with a temperature-controlled heating mantle, reflux condenser and magnetic stirrer. The volume of the flask is chosen in such a way that the contents of the entire reaction mixture do not exceed 50% of the flask's nominal capacity.

10 Sufficient diethyl ether (EM Science absolute grade) is added to make the ratio of isonicotinic acid hydrazide to ether to be about 0.10 to 1.00. This solvent choice is necessary to insure that the desired diacylhydrazine product is formed and not the triacylhydrazine product of over-acylation.

15 The mixture is brought to the boil and remains a heterogeneous mixture throughout the entire procedure. A 1.33 Molar solution of the appropriate carboxylic acid anhydride in ether is added through the top of the condenser in several small portions over a period not to exceed 0.004 moles per minute.

After the addition is complete, the mixture is stirred and refluxed for an additional 20 minutes. The mixture is allowed to cool to room temperature and to stand over night. A white solid forms and this is the desired product.

20 The white solid product thus obtained is filtered off by gravity using Whatman No. 1 filter paper, washed with cold ether (4 mL per 0.010 mole of product, assuming complete conversion) and allowed to air dry. The product is then analyzed and characterized by the usual means, including melting point, infrared, near infrared, mass and magnetic resonance spectroscopy and elemental analysis.

## Experimental Procedures-Diacylhydrazines

### Example 1. 1-Isonicotinoyl-2-formylhydrazine.

This reaction was performed to produce 1-isonicotinoyl-2-formylhydrazine by mixing  
5 formic acid (88% by weight, 2 mL) with isonicotinic acid hydrazide (1.03 g) and allowing the  
mixture to stir at room temperature. An exotherm was noted, heat was produced, and after  
several minutes a clear fluorescent yellow solution was obtained. The yellow solution was  
permitted to stand over night, poured into ether (20 mL), yielding a white crystalline solid. The  
solid was stirred and crushed with ether (20 mL) and allowed to air dry for several hours, giving  
10 the diacylhydrazine 1, 1-isonicotinoyl-2-formylhydrazine (1.12 g, 90%) mp 94-96 °C, lit mp [H.  
Fox, *U.S. Patent* 2,689,852; Sept 21, 1954; *Chem. Abstr.*, 1955, 49, 14813d] 96-98 °C; IR  $\nu$   
3252, 1695, 1662, 1611, 1556, 1415, 1333, 1246, 1227, 1069, 1021, 850  $\text{cm}^{-1}$ .

### Example 2. 1-Isonicotinoyl-2-acetylhydrazine.

15 1-Isonicotinoyl-2-acetylhydrazine was prepared using the Acylation Method in the  
General Structural Outline for Diacylhydrazine Synthesis in a like manner in 96% yield, mp 158-  
160 °C (from butyl acetate), lit mp [A. Novotny, Z. Brezik, J. Pridal and K. Kalfurs, *Ceskoslov.*  
*farm.*, 1958, 7, 517-520; *Chem. Abstr.*, 1959, 53, 10191c] 162.2-162.5 °C; IR  $\nu$  3214, 1699,  
1657, 1555, 1514, 1296, 1222, 997, 838, 755  $\text{cm}^{-1}$ .

### Example 3. 1-Isonicotinoyl-2-propionylhydrazine.

1-Isonicotinoyl-2-propionylhydrazine was prepared using the Acylation Method in the  
General Structural Outline for Diacylhydrazine Synthesis in a like manner in 95% yield, mp  
131 °C, lit mp [A. Novotny, Z. Brezik, J. Pridal and K. Kalfurs, *Ceskoslov. farm.*, 1958, 7, 517-

520; *Chem. Abstr.*, 1959, 53, 10191c] 130°C; IR  $\nu$  3195, 1671, 1599, 1551, 1494, 1403, 1218, 1060, 859, 845  $\text{cm}^{-1}$ .

Example 4. 1-Isonicotinoyl-2-butyrylhydrazine.


1-Isonicotinoyl-2-butyrylhydrazine was prepared using the Acylation Method in the General Structural Outline for Diacylhydrazine Synthesis in a like manner in 87% yield, mp 142°C, lit mp [A. Novotny, Z. Brezik, J. Pridal and K. Kalfurs, *Ceskoslov. farm.*, 1958, 7, 517-520; *Chem. Abstr.*, 1959, 53, 10191c] 140°C; IR  $\nu$  3195, 1598, 1552, 1495, 1402, 1217, 1085, 881, 845  $\text{cm}^{-1}$ .

Example 5. 1-Isonicotinoyl-2-valeroylhydrazine.

1-Isonicotinoyl-2-valeroylhydrazine was formed in the following way. This compound was prepared using the Acylation Method in the General Structural Outline for Diacylhydrazine Synthesis. To a heterogeneous mixture of isonicotinic acid hydrazide (1.38 g, 10.1 mmol) in boiling ether (15 mL) contained in a 100 mL round bottom flask fitted for reflux with a temperature-controlled heating mantle and reflux condenser and for magnetic stirring was added in several small portions over 5 minutes valeric anhydride (4.1 mL,  $D = 0.92 \text{ g/mL}$ , 3.77 g, 20.3 mmol) dissolved in ether (15 mL). After the addition was complete, the mixture was stirred and refluxed a further 20 minutes, then allowed to cool to room temperature and stand over night. The white micaceous crystalline solid thus obtained was filtered off by gravity and washed liberally with ether (40 mL) to give the 1-isonicotinoyl-2-valeroylhydrazine compound (1.73 g, 78%), mp 162 °C (from butyl acetate); IR  $\nu$  3192, 1599, 1551, 1493, 1400, 1119, 1085, 1062, 869, 846, 756  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $C_{11}H_{15}N_3O_2$ : C, 59.71; H, 6.83. Found: C, 59.86; H, 6.75.

#### B. Thioacylation Procedure.



The thioacylated compounds are prepared by the reactions of isonicotinic acid hydrazide with mustard oils (isothiocyanates).

Isonicotinic acid hydrazide (Fluka A.-G., Lancaster or Aldrich Chemical Companies) is used to prepare a 0.4 Molar solution in absolute ethanol, at reflux. The ethanol is used as received from Pharmco, Incorporated.

The preparation of the solution at reflux is done by mixing the required weight of isonicotinic acid hydrazide with the necessary volume of absolute ethanol in a standard taper round bottom flask fitted for reflux with a temperature-controlled heating mantle, carborundum boiling chip and condenser. The volume of the flask is chosen in such a way that the contents of the entire reaction mixture do not exceed 50% of the flask's nominal capacity.

The mixture of isonicotinic acid hydrazide and ethanol is brought to the boil and forms a clear colorless solution. The appearance of pronounced yellow color or pink tinge in the boiling mixture is unacceptable and generally indicates impure isonicotinic acid hydrazide.

To the clear colorless solution at the boil is added through the condenser the appropriate mustard oil (isothiocyanate) as a 0.60 Molar solution in ethanol at a rate no greater than 0.0006

moles per minute. Refluxing is continued for one hour, at which point the solution is usually yellow to orange, depending on the individual nature of the mustard oil.

The reaction mixture is allowed to cool to room temperature and to stand over night, depositing white crystals of product. The material is filtered off by gravity filtration using Whatman No. 1 filter paper and allowed to stand on the filter cake to dry for several hours, yielding the thioacylated product, generally in analytically pure form. The arylthioamido product is then analyzed and characterized by the usual means, including melting point, infrared, mass and magnetic resonance spectroscopy and elemental analysis.

### Examples

#### Example 1. 1-Phenylthioamido-2-isonicotinoylhydrazine.

This compound was prepared using the Thioacylation Method in the General Structural Outline for Diacylhydrazine Synthesis. To a clear colorless solution of isonicotinic acid hydrazide (0.82 g, 6.0 mmol) in boiling ethanol (50 mL), in a 100 mL round bottom flask fitted for reflux, was added 0.81 g (6.0 mmol) of phenylisothiocyanate dissolved in ethanol (10 mL) in several small portions over a period of 10 minutes. Refluxing was continued for one hour, at which point the solution was orange. The reaction mixture was permitted to stand at room temperature over night, depositing white crystals of product. The material was filtered off by gravity and allowed to stand on the filter cake to dry for several hours, yielding 1.18 g (72%) of the title compound, mp 176-177°C, IR  $\nu$  3300-3150, 1682, 1666, 1598, 1498, 1404, 1303, 1255, 1215, 1142, 1101, 1065, 1030, 1001, 964, 944, 902, 843, 754, 741, 690  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{12}\text{N}_4\text{SO}$ : C, 57.34; H, 4.44. Found: C, 57.41; H, 4.43.

#### Example 2. 1-para-Tolylthioamido-2-isonicotinoylhydrazine.

This compound was prepared using the Thioacylation Method in the General Structural Outline

for Diacylhydrazine Synthesis. To a clear colorless solution of isonicotinic acid hydrazide (0.82 g, 6.0 mmol) in boiling ethanol (50 mL), in a 100 mL round bottom flask fitted for reflux, was added 0.89 g (6.0 mmol) of para-tolylisothiocyanate dissolved in ethanol (10 mL) in several small portions over a period of 10 minutes. Refluxing was continued for one hour, at which point the solution was yellow-orange. The reaction mixture was permitted to stand at room temperature over night, depositing white crystals of product. The material was filtered off by gravity and allowed to stand on the filter cake to dry for several hours, yielding 1.46 g (91%) of the title compound, mp 182-184°C, IR  $\nu$  3300-3150, 1681, 1667, 1600, 1552, 1512, 1305, 1255, 1211, 1140, 1065, 1020, 996, 965, 940, 905, 844, 816, 753, 720  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{14}\text{H}_{14}\text{N}_4\text{SO}$ : C, 58.72; H, 4.93. Found: C, 58.81; H, 4.93.

#### Example 3. 1-para-Bromophenylthioamido-2-isonicotinoylhydrazine.

This compound was prepared using the Thioacylation Method in the General Structural Outline for Diacylhydrazine Synthesis from isonicotinic acid hydrazide and para-bromophenylisothiocyanate in 76% yield, mp 178-180°C, IR  $\nu$  3300-3150, 1672, 1600, 1548, 1299, 1254, 1212, 1145, 1065, 1011, 1000, 936, 900, 824, 750, 722  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{13}\text{H}_{11}\text{N}_4\text{SOBr}$ : C, 44.46; H, 3.16. Found: C, 44.42; H, 3.26.

#### Example 4. 1-para-Chlorophenylthioamido-2-isonicotinoylhydrazine.


This compound was prepared using the Thioacylation Method in the General Structural Outline for Diacylhydrazine Synthesis from isonicotinic acid hydrazide and para-chlorophenylisothiocyanate in 77% yield, mp 181-182°C, IR  $\nu$  3300-3150, 1674, 1650, 1596, 1550, 1512, 1404, 1300, 1256, 1213, 1148, 1090, 1064, 1044, 1000, 965, 937, 902, 828, 752, 717

cm<sup>-1</sup>.

*Analysis.* Calculated for C<sub>13</sub>H<sub>11</sub>N<sub>4</sub>SOCl: C, 50.90; H, 3.61. Found: C, 50.91; H, 3.70.

5

### General Structural Outline for Oxadiazoline Synthesis



Oxadiazolines are prepared by the reactions of Schiff bases with carboxylic acid anhydrides. Reaction conditions, specifically including reaction times, and work-up methods, specifically including a base wash, are critical to insure that the products of the syntheses are obtained in acceptable form.

20

The appropriate Schiff base is weighed into a pear-shaped standard taper flask. The volume of the flask is chosen in such a way that the contents of the entire reaction mixture do not exceed 50% of the flask's nominal capacity. A boiling chip is added to the flask, and the flask is fitted for reflux with a temperature-controlled heating mantle and reflux condenser.

Sufficient carboxylic acid anhydride (typically acetic anhydride) is added to the flask to make the solution about a 0.25-0.30 Molar solution of Schiff base in anhydride. This characteristically makes the mole ratio of Schiff base to anhydride to be about 0.028 to 1.00. The mixture is brought to the boiling point, and refluxing is continued for an hour. During the hour of refluxing, the reaction mixture changed color and may vary in color from light yellow to deep orange.

Following the hour of refluxing, the hot mixture is turned out onto a large watchglass and allowed to air dry in the hood over night. The solid tan-colored material thus obtained shows the expected infrared bands for the oxadiazoline, viz., infrared bands at *ca.* 1670, 1630, 1600, 1550 and 1520, diagnostic for the completion of the desired reaction.

The material is taken up in sufficient ether (EM Science absolute grade) to make a 0.04 to 0.05 Molar solution of product oxadiazoline in ether, assuming complete conversion of Schiff base to oxadiazoline, i.e. the material is taken up in an amount of ether six times the volume of anhydride used for the reaction.

In a large beaker with at least twice the nominal capacity of the mixture it will contain, fitted with a magnetic stirrer, the ether solution is stirred vigorously over 10% aqueous sodium bicarbonate solution for 90 minutes. This base wash is necessary to insure that the final product is obtained in pure form.

The mixture is transferred to a separatory funnel, and the ether layer is separated. The volume of the ether layer is noted. The aqueous layer is then extracted with three portions of ether, each of which is one-half the volume so noted.

The combined ether extracts are dried over anhydrous magnesium sulfate (Baker) for several hours, gravity filtered through Whatman No. 1 filter paper and evaporated on a large watchglass to give the oxadiazoline. The beige to tan solid product thus obtained is then analyzed



and characterized by the usual means, including melting point, infrared, mass and magnetic resonance spectroscopy and elemental analysis.

## 5 Experimental Procedures-Oxadiazolines

### Example 1. 2,2-Dimethyl-3-propionyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared by the General Structural Outline for Oxadiazoline Synthesis from the isonicotinoylhydrazone of acetone and propionic anhydride. Thus to the isonicotinoylhydrazone of acetone (0.355 g, 2.01 mmol) in a standard 50 mL pear-shaped flask containing a boiling chip and fitted for reflux with a temperature-controlled heating mantle and reflux condenser was added propionic anhydride (10 mL, an excess). The mixture was brought to the boiling point, and refluxing was continued for an hour. After 45 minutes of reflux, the sample had become a deep orange color. Following the hour of refluxing, the hot mixture was turned out onto a watchglass and allowed to air dry in the hood over night. The material thus obtained (100% of theory) showed the expected infrared bands for the oxadiazoline, and only a small amount of the anhydride remained. The material was taken up in ether (30 mL), and the ether solution was stirred vigorously over 10% aqueous sodium bicarbonate solution for 90 minutes, during which time a substantial amount of the color passed into the aqueous layer. The ether was drawn off, and the aqueous portion was extracted with 3 x 15 mL portions of ether. The combined ether layers were dried over anhydrous magnesium sulfate, filtered and evaporated on a watchglass in the hood to give the product oxadiazoline (0.397 g, 85%) as a tan semisolid mass; IR  $\nu$  3030, 1676, 1625, 1597, 1551, 1498, 1093, 840, 826  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_2$ : C, 61.79; H, 6.48. Found: C, 62.16; H, 6.67.

Example 2. 2,2-Dimethyl-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared by the General Structural Outline for Oxadiazoline Synthesis from the isonicotinoylhydrazone of acetone and acetic anhydride in 99% yield as hexagonal plates, mp 117-118 °C, lit mp [H. Yale, K. Losee, J. Martins, M. Holsing, F. Perry and J. Bernstein, *J. Am. Chem. Soc.*, 75, 1933 (1953)] 109-111 °C; IR  $\nu$  3032, 1665, 1625, 1598, 1550, 1505, 1085, 1047, 1039, 968, 945, 839, 826, 735  $\text{cm}^{-1}$ .

Example 3. 2,2-Pentamethylene-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared from the isonicotinoylhydrazone of cyclohexanone and acetic anhydride. Specifically, to the isonicotinoylhydrazone of cyclohexanone (0.502 g, 2.31 mmol), dissolved in toluene (10 mL) in a 50 mL pear-shaped flask containing a boiling chip and fitted for reflux with a temperature-controlled heating mantle and reflux condenser was added acetic anhydride (1 mL, 11 mmol), dissolved in toluene (5 mL). The mixture was brought to the boiling point, and there by was produced a clear yellow solution. Refluxing was continued for 8.5 hours. Following the period of refluxing, the hot mixture was turned out onto a watchglass and allowed to air dry in the hood to obtain the product, 0.52 g (87%), mp 106-107 °C (from petroleum ether), lip mp [R. Sagitulin and A. Kost, *Vestnik. Moskov. Univ., Ser. Mat., Mekh., Astron., Fiz. i Khim.*, 14, 187 (1959); *Chem. Abstr.*, 54, 17383h (1959)] 104-105 °C; IR  $\nu$  3030, 1678, 1628, 1598, 1552, 1504, 892, 846, 827, 734, 665  $\text{cm}^{-1}$ .

Example 4. 2-(2,6-Dichlorophenyl)-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared from the isonicotinoylhydrazone of 2,6-dichlorobenzaldehyde and acetic anhydride, using the General Structural Outline for

Oxadiazoline Synthesis in 35% yield, mp 163 °C; NMR (300 Mhz)  $\delta$  8.77 (2H, d, J = 6 cps), 7.7-7.5 (6H, m including emergent d at 7.6, J = 6 cps), 2.2 (3H, s).

*Analysis.* Calculated for C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>Cl<sub>2</sub>: C, 53.59; H, 3.30. Found: C, 53.58; H, 3.37.

5 Example 5. 2-Methyl-2-phenyl-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared from the isonicotinoylhydrazone of acetophenone and acetic anhydride, using the General Structural Outline for Oxadiazoline Synthesis in 75% yield, mp 79-81°C; IR  $\nu$  1667, 1628, 1597, 1551, 1329, 1311, 1258, 1216, 1199, 1157, 1084, 1062, 1028, 989, 956, 892, 830, 767, 722 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 Mhz)  $\delta$  8.7 (2H, d, J = 6 cps), 7.7 (2H, d, J = 6 cps), 7.5-7.3 (5H, m), 2.3 (3H, s), 2.2 (3H, s); <sup>13</sup>C NMR  $\delta$  166, 153, 151, 138, 132, 129, 127, 125, 121, 102, 22.5, 22.7.

10 Example 6. 2-(2,6-Difluorophenyl)-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

15 The title compound was prepared from the isonicotinoylhydrazone of 2,6-difluorobenzaldehyde and acetic anhydride, using the General Structural Outline for Oxadiazoline Synthesis in 31% yield, mp 119-121°C; IR  $\nu$  1673, 1624, 1594, 1554, 1334, 1312, 1295, 1209, 1092, 1062, 1008, 988, 974, 886, 825, 790, 730, 703, 663, 632 cm<sup>-1</sup>; NMR (300 Mhz)  $\delta$  8.75 (2H, br d, J = 6 cps), 7.75 (2H, d, J = 6 cps), 7.65-7.15 (4H, m from which emerges singlet at 7.5), 2.2 (3H, s).

20 *Analysis.* Calculated for C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>F<sub>2</sub>: C, 59.41; H, 3.66. Found: C, 59.17; H, 3.70.

Example 7. 2-(4-Chloro-3-nitrophenyl)-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared from the isonicotinoylhydrazone of 4-chloro-3-nitrobenzaldehyde and acetic anhydride, using the General Structural Outline for Oxadiazoline

Synthesis in 50% yield, mp 122°C; IR  $\nu$  1663, 1626, 1597, 1574, 1554, 1532, 1310, 1264, 1212, 1167, 1135, 1089, 1052, 1009, 974, 924, 914, 869, 840, 831, 815, 754, 730, 700  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{15}\text{H}_{11}\text{N}_4\text{O}_4\text{Cl}$ : C, 51.96; H, 3.20. Found: C, 51.75; H, 3.33.

5 Example 8. 2-(2-Nitrophenyl)-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared from the isonicotinoylhydrazone of 2-nitrobenzaldehyde and acetic anhydride, using the General Structural Outline for Oxadiazoline Synthesis in 91% yield, mp 159°C; IR  $\nu$  1663, 1628, 1598, 1581, 1551, 1522, 1414, 1333, 1314, 1270, 1205, 1172, 1146, 1088, 1082, 1032, 988, 896, 851, 828, 798, 750, 714, 705  $\text{cm}^{-1}$ .

*Analysis.* Calculated for  $\text{C}_{15}\text{H}_{12}\text{N}_4\text{O}_4$ : C, 57.70; H, 3.87. Found: C, 57.65; H, 3.98.

Example 9. 2-(3,4-Difluorophenyl)-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

To the isonicotinoylhydrazone of 3,4-difluorobenzaldehyde (0.38 g, 1.4 mmol) in a 50 mL pear-shaped flask containing a boiling chip and fitted for reflux with a temperature-controlled heating mantle and reflux condenser was added acetic anhydride (5 mL, 49 mmol, an excess). The mixture was brought to the boiling point, and refluxing was continued for an hour. Following the hour of refluxing, the hot mixture was turned out onto a watchglass and allowed to air dry in the hood over night. The material obtained showed the expected infrared bands for the title oxadiazoline, and only a small amount of the anhydride remained. The material was taken up in ether (30 mL), and the ether solution was stirred vigorously over 10% aqueous sodium bicarbonate solution for 90 minutes. The ether was drawn off, and the aqueous portion was extracted with 3 x 15 mL portions of ether. The combined ether layers were dried over anhydrous magnesium sulfate, filtered and evaporated on a watchglass in the hood to give the title oxadiazoline (0.44 g, 100%) as a slightly hygroscopic beige solid, mp 112-113 °C; IR  $\nu$

1667, 1629, 1600, 1552, 1519, 1413, 1339, 1321, 1281, 1217, 1184, 1116, 1092, 1076, 1066,  
1043, 990, 969, 954, 925, 872, 828, 818, 794, 770, 751, 704  $\text{cm}^{-1}$ ; NMR (300 Mhz)  $\delta$  8.75 (2H,  
d, J = 6 cps), 7.75-7.38 (5H, m, including emergent 7.75 d, J = 6 cps), 7.23 (1H, s), 2.2 (3H, s);  
high resolution mass spectrum (FAB method) m/z 304.0889 (M + H) ( $\text{C}_{15}\text{H}_{11}\text{N}_3\text{O}_2\text{F}_2$  + H  
5 requires 304.0898).

*Analysis.* Calculated for  $\text{C}_{15}\text{H}_{11}\text{N}_3\text{O}_2\text{F}_2 \times 0.25 \text{ H}_2\text{O}$ : C, 58.53; H, 3.76. Found: C,  
58.78; H, 3.67.

#### Example 10. 2-(3,4-Dichlorophenyl)-3-acetyl-5-(4-pyridyl)-1,3,4-oxadiazoline.

The title compound was prepared from the isonicotinoylhydrazone of 3,4-  
dichlorobenzaldehyde and acetic anhydride, using the General Structural Outline for  
Oxadiazoline Synthesis in 36% yield, mp 101-104 °C, IR  $\nu$  1667, 1628, 1598, 1552, 1410, 1365,  
1334, 1314, 1266, 1212, 1169, 1130, 1094, 1072, 1032, 990, 926, 885, 857, 825, 745, 723, 702  
cm<sup>-1</sup>.

*Analysis.* Calculated for  $\text{C}_{15}\text{H}_{11}\text{N}_3\text{O}_2\text{Cl}_2$ : C, 53.59; H, 3.30. Found: C, 53.24; H, 3.45.

#### Results

##### In vitro Testing against *M.tuberculosis* and Nontuberculous Mycobacteria (NTB)

The compounds of the invention have been initially evaluated by the Tuberculosis Antimicrobial  
Acquisition and Coordinating Facility (TAACF), and all show significant activity in the Primary  
20 Assay.

##### Summary of TAACF Methods

Primary screening is conducted at 12.5 or 6.25 ug/ml (or molar equivalent of highest molecular  
weight compound in a series of congeners) against *Mycobacterium tuberculosis* H37Rv (ATCC  
27294) in BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA).

Compounds exhibiting fluorescence are tested in the BACTEC 460-radiometric system.

Compounds effecting <90% inhibition in the primary screen (MIC > 6.25 ug/ml) are not generally evaluated further. Compounds demonstrating at least 90% inhibition in the primary screen are re-tested at lower concentrations against *M. tuberculosis* H37Rv to determine the actual minimum inhibitory concentration (MIC) in the MABA. The MIC is defined as the lowest concentration effecting a reduction in fluorescence of 90% relative to controls. Concurrent with the determination of MICs, compounds are tested for cytotoxicity (IC50) in VERO cells at concentrations less than or equal to 62.5ug/ml or 10 times the MIC for *M. tuberculosis* H37Rv. After 72 hours exposure, viability is assessed on the basis of cellular conversion of MTT into a formazan product using the Promega CellTiter 96 Non-radioactive Cell Proliferation Assay.

Compounds for which the IC50:MIC (SI) ratio is >10 will have *in vitro* activity confirmed in the BACTEC 460 at 6.25ug/ml. Compounds are then tested for killing of *M. tuberculosis* Erdman (ATCC 35801) in monolayers of mouse bone marrow macrophages. (EC99 and EC90; lowest concentration effecting a 90% and 99% reduction in colony forming units at 7 days compared to drug-free controls) at 4-fold concentrations equivalent to 0.25, 1, 4 and 16 times the MIC.

Concurrent with the testing of compounds in macrophages, MICs are determined in the MABA for three strains of drug-resistant *M. tuberculosis*, (each strain resistant to a single TB drug) as well as *M. avium*. Typically, all compounds progressing to this stage of screening has been tested against *M. avium* (ATCC 25291), *M. tuberculosis* strains resistant to isoniazid (ATCC 35822), rifampin (ATCC 35838), and one other drug resistant strain (the latter determined by the compound type) as well as the drug-sensitive strains H37Rv and Erdman. Minimum bactericidal concentration (MBC) is then determined for *M. tuberculosis* H37Rv and Erdman (and the corresponding drug-resistant strain for analogs of known antitubercular drugs) by subculturing onto drug-free solid following exposure in supplemented Middlebrook 7H9 media to drug

concentrations equivalent to and higher than the previously determined MICs of the respective strains.



The EC90 represents bacteriostatic activity, and the EC99 indicates bactericidal activity.

The EC90 denotes the effective concentration to give a 90% reduction in intramacrophage  
5 bacteria relative to a drug-free control. Since this concentration maintains roughly the level of  
the initial inoculum, the value represents the necessary amount of drug to maintain a static level  
of bacteria within the macrophage host. The EC99 value represents a one log reduction and thus  
gives a measure of the bactericidal activity of the drug. The ratio EC90/MIC provides a measure  
of bioavailability and metabolism of the active agent within the living host, since it compares the  
10 *in vitro* activity against the bacillus to the activity against the bacillus while it lives within the  
host cell. The smaller the EC90/MIC, the better the agent, with the threshold for further  
screening ~4 (*viz.*, the value for INH itself).





Table 1: *M.tuberculosis* Assay

SAMPLE ID	STRUCTURE	ASSAY	MIC (ug/ml)	SI	MIC H37R v (ug/ml)	MIC Exdman (ug/ml)	MIC INH-R (ug/ml)	INH-R MIC	MIC RMP-R (ug/ml)	RMP-R MIC	MIC EMB-R (ug/ml)	EMB-R MIC	MIC ETA-R (ug/ml)	ETA-R MIC
132358		Bactec	0.1	>1250	0.1	0.1	>32	>32	0.1	1	>32	>32	0.8	0.08
132532		Bactec	0.1	68	0.1	0.1	>32	>32	0.1	1	>32	>32	1.6	0.16

00000T"2E/66960

Table 2: *M. avium* Assay











SAMPLE ID	STRUCTURE	ASSAY	MIC (ug/ml)
102044		BACTEC	0.78
102866		BACTEC	3.25
117150		BACTEC	>3.25

Table 3: *M. avium* Assay

SAMPLE ID	STRUCTURE	ASSAY	MIC (ug/ml)
132358		BACTEC	>3.20
132532		BACTEC	>3.20

000001" 23/66960

Table 4: *M.tuberculosis* Assay

SAMPLE ID	STRUCTURE	MIC (ug/ml)	SI	ASSAY DATE	EC 90	EC99	EC 90: MIC	COMMENT
102674		0.03	40000	11/12/98	0.08	>0.4	2.67	EC90 RMP = .1; EC99 RMP = .6
102752		0.1	10000	11/12/98	0.03	0.14	0.3	EC90 RMP = .06; EC99 RMP = .36
101743		0.2	50000	11/12/98	0.01	>3.2	0.05	EC90 RMP = .1; EC99 RMP = .6
102858		0.2	4000	11/12/98	0.03	0.12	0.15	EC90 RMP = .02; EC99 RMP = .23
102090		0.1	2000	11/12/98	0.18	>1.6	1.8	EC90 RMP = .1; EC99 RMP = .6










102787		0.1	2000	11/12/98	0.04	0.12	0.4	EC90 RMP = .02; EC99 RMP = .23
102866		0.1	1520	11/12/98	0.04	0.15	0.4	EC90 RMP = .02; EC99 RMP = .23
102044		0.2	1000	11/12/98	0.02	0.08	0.1	EC90 RMP = .02; EC99 RMP = .23
103167		0.1	1000	11/12/98	0.02	0.07	0.2	EC90 RMP = .02; EC99 RMP = .23





Table 5: *M.tuberculosis* Assay

SAMPLE ID	STRUCTURE	MIC (ug/ml)	SI	ASSAY DATE	EC 90	EC99	EC 90: MIC	COMMENT
102871		0.2	500	11/12/98	0.06	0.23	0.3	EC90 RMP = .02; EC99 RMP = .23
102094		0.2	374	11/12/98	0.08	>3.2	0.4	EC90 RMP = .1; EC99 RMP = .6
103062		0.2	250	11/12/98	0.03	0.15	0.15	EC90 RMP = .02; EC99 RMP = .23
102043		0.05	126	11/12/98	0.04	>0.8	0.8	EC90 RMP = .1; EC99 RMP = .6
111298		0.025		11/17/98	0.03	0.16	1.2	EC90 RMP = .11; EC99 RMP = .37; EC90 INH = .21; EC99 INH = >.4

000007" 26.265960

Table 6: *M. tuberculosis* Assay




SAMPLE ID	STRUCTURE	ASSAY	MIC (ug/ml)	SI	MIC H37Rv (ug/ml)	MIC ERDMAN (ug/ml)	MIC INH-R (ug/ml)	MIC RMP-R (ug/ml)	RMP-R MIC	MIC TAC-R (ug/ml)	TAC-R MIC
102866		BACTEC	0.1	1520	<0.05	<0.05	3.25	<0.05	<0.5	>3.25	>32.5
102044		BACTEC	0.2	1000	<0.1	<0.1	3.13	<0.1	<0.5	3.13	15.65
117150		BACTEC	0.1		<0.05	<0.05	>3.25	<0.05	<0.25	>3.25	>32.05

Table 7: *M. tuberculosis* Assay




SAMPLE ID	STRUCTURE	% Inhibition	Test Date	Assay	MIC (ug/ml)	IC50 (ug/ml)	SI	Comment
122489		99	3/2/99	Alamar	<0.2	>125	>625	MIC of RMP=0.06 µg/ml. IC50 (INH)>1000; RMP-68; DMSO=0.0101; DMSO at 1:50>1000)
122490		99	3/2/99	Alamar	<0.2	>10	>50	MIC of RMP=0.06 µg/ml. IC50 (INH)>1000; RMP=68; DMSO=0.0101; DMSO at 1:50>1000)
114353				Bactec	>6.25			

Table 8: *M. tuberculosis* Assay




Sample ID	Structure	MIC (ug/ml)	SI	Assay	MIC H37Rv (ug/ml)	MIC Erdman (ug/ml)	MIC INH-r (ug/ml)	INH-R:MIC	MIC RMP-R (ug/ml)	RMP-R:MIC	MIC EMB-R (ug/ml)	EMB-R:MIC
111992			>8000	Bactec	0.05	0.1	>0.75		0.1		0.1	
114353			>2000	Bactec	<0.1	<0.1	<6.25		<0.1		<0.1	
111298		0.02		Bactec	0.05	0.05	>0.75	>30	0.05	2	0.05	2

Table 9: *M.tuberculosis* Assay


Sample ID	Structure	MIC (ug/ml)	SI	Assay Date	Assay	MBC vs H37Rv (ug/ml)	MBC vs RMP-R (ug/ml)	MBC vs INH-r (ug/ml)	Comment
101702		0.39	>2631.6	7/15/98	ALAMAR	>=0.19	0.39	>12.5	MIC or RMP (ug/ml) vs H37Rv=0.5; vs RMP-R>8; vs INH-R=0.5.

Table 10: *M. avium* Assay








Sample ID	Structure	Test Date	Assay	MIC (ug/ml)	% Inhibition	Comment
123668		12/11/98	Bactec	<12.5	98	MIC Clarithromycin=2µg/ml vs. <i>M. avium</i> .
123669		12/11/98	Bactec	>12.5	65	MIC Clarithromycin=2µg/ml vs. <i>M. avium</i> .
122489		12/11/98	Bactec	>12.5	45	MIC Clarithromycin=2µg/ml vs. <i>M. avium</i> .
122490		12/11/98	Bactec	>12.5	20	MIC Clarithromycin=2µg/ml vs. <i>M. avium</i> .

Table 11: *M. avium* Assay

Sample ID	Structure	Test Date	Assay	MIC (ug/ml)	% Inhibition		Comment
117899		9/3/98	Alamar	>12.5	12	-	MIC Clarithromycin = 2µg/ml vs. <i>M. avium</i> .
117150		9/1/98	Alamar	>12.5	0	-	MIC Clarithromycin = 4µg/ml.
126719		9/11/98	Bactec	>12.5	84	-	MIC RMP=0.25 µg/ml, 99% inhibition vs. <i>M. tuberculosis</i> .









09699732 103000

Table 12: *M. avium* Assay

Sample ID	Structure	Test Date	Assay	MIC (ug/ml)	% Inhibition	Comment
125304		7/22/98	Bactec	>12.5	15	- MIC RMP=0.125 ug/ml vs. <i>M. tuberculosis</i>

Table 13: *M.tuberculosis* Assay

Sample ID	Structure	Test Date	MIC (ug/ml)	% Inhibition	Comment
122492		5/19/98	<12.5	99	MIC RMP=0.25 ug/ml vs. <i>M.tuberculosis</i> .
122487		5/19/98	<12.5	98	MIC RMP=0.25 ug/ml vs. <i>M.tuberculosis</i> .
122491		5/19/98	<12.5	98	MIC RMP=0.25 ug/ml vs. <i>M. tuberculosis</i> .
123668		5/21/98	<12.5	97	MIC RMP=0.25 ug/ml vs. <i>M. tuberculosis</i> .
122697		5/98/98	>12.5	79	MIC RMP=0.25 ug/ml vs. <i>M. tuberculosis</i> .

123667		5/21/98	>12.5	38	-	MIC RMP=0.25 µg/ml vs. M. tuberculosis.
--------	---	---------	-------	----	---	---

### In Vitro Testing

Methods for the determination of *in vitro* activities were used are discussed in detail in the literature. Schoen et al., *Antimicrobial Agents and Chemotherapy*, **42**, 3315-3316 (1998). In brief, stock solutions of the drugs were prepared by dissolving them in double-distilled water. Solutions were sterilized by passage through a 0.22- $\mu$ m-pore-size membrane filter and were diluted 20-fold with modified 7H10 broth, pH 6.6, with 10% oleic acid, albumin, dextrose and catalase (OADC) enrichment and 0.05% Tween 80. Serial twofold dilutions were prepared in modified 7H10 broth, with varying concentrations of drug. Isolates were grown at 37°C in modified 7H10 broth for 3 to 5 days on a rotary shaker and were then diluted in modified 7H10 broth to yield a final concentration of approximately  $2.5 \times 10^4$  CFU/ml. The final volume in each assay tube was 2 ml. The inoculum size was measured by titration and counting from duplicate 7H10 agar plates supplemented with 5% OADC. The isolates maintained an appropriate phenotype on the titer plates. A tube without drug was included as a positive control. Tubes were incubated in ambient air on a rotary shaker (150 rpm) for 5 to 7 days, until good growth was present in the control tube. The MIC was defined as the lowest drug concentration that yielded no turbidity.

### Data

20	<u>Compound</u>	<u>MIC (<i>M. avium</i> 101)</u>
	MJH-92-I-81	1 ug/ml
	MJH-92-I-87	1
	MJH-98-I-48c	4
	MJH-98-I-48d	4
25	MIC Clarithromycin = 2 ug/ml vs. <i>M. avium</i> 101	

	<u>Compound</u>	<u>MIC (<i>M. kansasii</i> swank)</u>
	MJH-92-I-81	1 ug/ml
30	MJH-92-I-87	1
	MJH-98-I-48c	2

MJH-98-I-48d 1  
MIC INH = 1 ug/ml vs. *M. kansasii* swank

In vivo Testing against *M. tuberculosis* in a Murine Model

The compounds were evaluated at 25mg/kg in comparison to INH at a like concentration. Mice were treated 5 days per week by gavage for four weeks. This model, as described in M. H. Cynamon, Y. Zhang, T. Harpster, S. Cheng and M. DeStefano, *Antimicrobial Agents and Chemotherapy*, **43**, 2922-2924 (1999), provides a rigorous test of a compound's antituberculosis activity because of the high inoculum utilized (approximately 10 million viable organisms, Erdman). Referring to Fig. 2, the *in vivo* activity of one of these compounds was somewhat better than INH against an INH-susceptible organism. In brief, the experiments may be described as follows.

Medium

*Mycobacterium tuberculosis* Erdman (American Type Culture Collection 35801) was obtained from the American Type Culture Collection, Manassas, Virginia. This strain has been used previously for murine model studies. Klemens et al., *Antimicrobial Agents and Chemotherapy*, **38** 1476-1479 (1994); Klemens et al., *Antimicrobial Agents and Chemotherapy*, **40** 298-301 (1996). The organisms were grown on modified Middlebrook 7H10 broth, pH 6.6, supplemented with 10% OADC enrichment and 0.05% Tween 80 on a rotary shaker for 5 days at 37°C. The culture suspensions were diluted with modified 7H10 broth to yield 100 Klett units/ml (Klett-Summerson colorimeter; Klett Manufacturing, Brooklyn, New York), that is, approximately  $5 \times 10^7$  CFU/ml. The sizes of the inocula were determined by titration and counting from triplicate 7H10 agar plates supplemented with 10% OADC enrichment. The plates were incubated at 37°C in ambient air for 4 weeks prior to counting.

## Infection Studies


Six-week-old female CD-1 mice (Charles River, Wilmington, Massachusetts) were infected intravenously through a caudal vein. Each mouse received approximately  $10^7$  viable organisms suspended in 0.2 ml of modified 7H10 broth. There were eight mice per assay group. Treatment was started 1 week after infection. A group of untreated infected mice was sacrificed at the start of treatment (early controls). A second group of untreated mice was sacrificed at the conclusion of the treatment period (late controls). Treatment was given by gavage (0.2 ml) 5 days per week for 4 weeks. Mice were sacrificed by carbon dioxide inhalation at 3 to 5 days after administration of the last dose of drug. Spleens and right lungs were removed aseptically and ground in a tissue homogenizer. The number of viable organisms was determined by serial dilution and titration on 7H10 agar plates. The plates were incubated at  $37^{\circ}\text{C}$  in ambient air for 4 weeks prior to reading. Viable cell counts were converted to logarithms for comparisons.

All journal articles and reference citations provided above, in parentheses or otherwise, whether previously stated or not, are incorporated herein by reference.

The foregoing description has been limited to a specific embodiment of the invention. It will be apparent, however, that variations and modifications can be made to the invention, with the attainment of some or all of the advantages of the invention. Therefore, it is the object of the appended claims to cover all such variations and modifications as come within the true spirit and scope of the invention.

Having described my invention, what I now claim is:

1. An antimycobacterial compound which comprises the formula:



5 wherein  $R_1$  is H; and

$R_2$  is  $C_3$  to  $C_{14}$  alkyl,  $C_3$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy;

or a pharmaceutically acceptable salt thereof; or a pharmaceutical isomer thereof; or a combination of the same.

2. The antimycobacterial compound according to claim 1 wherein  $R_1$  is H; and

$R_2$  is  $CH=CHCH_3$  (trans),  $CH=CHCH_2CH_3$  (trans),  $CH=CHCH_2CH_2CH_3$  (trans),  $CH=CHCH_2CH_2CH_2CH_3$  (trans),  $C(CH_3)=CHCH_3$  (trans),  $CH=C(CH_3)CH_2CH_2CH=C(CH_3)_2$  (trans),  $CH=NNHCO-4-C_5HN$ ,  $CH_2CH(CH_3)CH_2CH_2CH=C(CH_3)_2$ ,  $4-C_6H_4-CH=NNHCO-4-C_5H_4N$ ,  $4-C_6H_4-O-CH_2CH_2CH_2CH_3$ ,  $(CH_2)_{11}CH_3$ ,  $4-C_6H_4NO_2$ ,  $C_6H_5$ ,  $2-C_6H_4OH$ ,  $4-OH-3-OCH_3C_6H_3$ ,  $4-C_6H_4OCH_3$ ,  $3-C_6H_4OCH_3$ ,  $(CH_2)_8CH_3$ ,  $(CH_2)_2CH_3$ ,  $2-C_6H_4OCH_3$ ,  $C(CH_3)=CHC_6H_5$  (trans),  $4-C_6H_4F$ ,  $3,5-di(CH_3)-4-O-C_7H_7$ ,  $2-F-4-OCH_3C_6H_3$ ,  $2-ClC_6H_4$ ,  $4-BrC_6H_4$ ,  $3-C_6H_4NO_2$ ,  $4-C_6H_4O(CH_2)_5CH_3$ ,  $2-Cl-5-NO_2C_6H_3$ ,  $4-Cl-3-NO_2C_6H_3$ ,  $2-C_6H_4NO_2$ ,  $2-6-$



di(Cl)C<sub>6</sub>H<sub>3</sub>, 2,3-di(Cl)C<sub>6</sub>H<sub>3</sub>, C<sub>6</sub>H<sub>5</sub>, 3,4-di(F)C<sub>6</sub>H<sub>3</sub>, 2,6-di(F)C<sub>6</sub>H<sub>3</sub>, 3,4-di(Cl)C<sub>6</sub>H<sub>3</sub>, 4-C<sub>6</sub>H<sub>4</sub>Cl, or CH=C(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>.

3. The antimycobacterial compound according to claim 1 wherein R<sub>1</sub> is CH<sub>3</sub>; and

R<sub>2</sub> = CH<sub>2</sub>COCH<sub>3</sub>, CH<sub>3</sub> CH<sub>2</sub>CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, or C<sub>6</sub>H<sub>5</sub>.

4. The antimycobacterial compound according to claim 1 wherein R<sub>1</sub> is

5 CH<sub>2</sub>CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; and

R<sub>2</sub> is CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.

5. The antimycobacterial compound according to claim 1 wherein R<sub>1</sub> is CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

and

R<sub>2</sub> is H<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>.


6. The antimycobacterial compound according to claim 1 wherein R<sub>1</sub> is 2-C<sub>5</sub>H<sub>4</sub>N; and

R<sub>2</sub> is 2 -C<sub>5</sub>H<sub>4</sub>N · 2H<sub>2</sub>O.

7. The antimycobacterial compound according to claim 1 where R<sub>1</sub>,R<sub>2</sub> is (CH<sub>2</sub>)<sub>4</sub>, (CH<sub>2</sub>)<sub>6</sub>


, 4-C<sub>6</sub>H<sub>8</sub>NNHCO-4-C<sub>5</sub>H<sub>4</sub>N.

8. The antimycobacterial compound according to claim 1 where R<sub>1</sub>, R<sub>2</sub> is




10

,





or





15


9. The antimycobacterial compound according to claim 1 wherein  $R_1$  is H; and  $R_2$  is




,




10






or



10. An antimycobacterial compound which comprises the formula:



wherein  $R_1$  is H;  $R_2$  is  $C_3$  to  $C_{14}$  alkyl,  $C_3$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle; and

$R_3$  is  $C_1$  or  $C_2$  alkyl; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable isomer thereof; or a combination of the same.

11. The antimycobacterial compound according to claim 10 wherein  $R_1$  is H;  $R_2$  is 2,6-di(Cl) $C_6H_3$ , 3- $NO_2$ -4-Cl- $C_6H_3$ , 3,4-di(F) $C_6H_3$ , 2- $C_6H_4NO_2$ , 3,4-di(Cl) $C_6H_3$  and 2,6-di(F) $C_6H_3$ ;  
and

5  $R_3$  is  $CH_3$ .

12. The antimycobacterial compounds according to claim 10 wherein  $R_1$  is  $CH_3$ ;  $R_2$  is  $CH_3$ ; and

$R_3$  is  $CH_2CH_3$  or  $CH_3$ .


13. The antimycobacterial compounds according to claim 10 wherein  $R_1$ ,  $R_2$  is  $(CH_2)_5$ ;  
and

$R_3$  is  $CH_3$ .

14. The antimycobacterial compound according to claim 10 wherein  $R_1$  is  $CH_3$ ;  $R_2$  is  $C_6H_5$ ; and

$R_3$  is  $CH_3$ .


15. An antimycobacterial compound which comprises the formula:



- 5 wherein  $R_1$  is  $C_2$  to  $C_6$  alkyl,  $C_2$  to  $C_6$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_{10}$  substituted alkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;
- 10 or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable isomer thereof; or a combination of the same.

16. The antimycobacterial compound according to claim 15 wherein  $R_1$  is  $NHC_6H_5$ ,  $NH-4-C_6H_4CH_3$ ,  $NH-4-C_6H_4Br$  or  $NH-4-C_6H_4Cl$ .

17. A method for producing an antimycobacterial compound comprising the formula of:




- 5 wherein  $R_1$  is H or  $CH_3$ ; and
- wherein  $R_2$  is  $C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo,
- 10 hydroxy, amino, or carboxy; or

wherein  $R_1R_2 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

which comprises:

15 refluxing



with absolute ethanol to produce a solution;

adding a carbonyl compound comprising the formula of:

20



wherein  $R_3 = H$  or  $CH_3$ ; and

25

wherein  $R_4 = C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

30

wherein  $R_3R_4 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

to the solution to produce a reaction mixture;

distilling the reaction mixture;


adding diethyl ether to the reaction mixture;

35

filtering the reaction mixture; and

drying the filtrate to produce **I**.

18. A method for producing an antimycobacterial compound comprising the formula of:



wherein  $R_1$  = wherein  $R_1$  is H or  $CH_3$

wherein  $R_2$  =  $C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or


wherein  $R_1R_2$  =  $C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

wherein  $R_3$  =  $C_1$  or  $C_2$  alkyl

which comprises:

refluxing






wherein  $R_1$  is H or  $CH_3$ ; and

wherein  $R_2$  is  $C_1$  to  $C_{14}$  alkyl,  $C_2$  to  $C_{10}$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_9$  substituted alkenyl,  $C_2$  to  $C_9$  substituted dialkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle, halo, hydroxy, amino, or carboxy; or

wherein  $R_1R_2 = C_4$  to  $C_8$  cycloalkyl or  $C_4$  to  $C_{10}$  substituted cycloalkyl;

with a carboxylic acid anhydride comprising the formula of:



wherein  $R = C_1$  or  $C_2$  alkyl

to produce a reaction mixture;

drying the reaction mixture;


adding ether to the reaction mixture to form a solution;

separating the ether from the solution to yield an aqueous layer;

extracting the aqueous layer with ether;

drying the ether extracts to produce **II**.


19. A method for producing a compound comprising the formula of:



wherein  $R_1 = C_1$  to  $C_6$  alkyl,  $C_2$  to  $C_6$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_{10}$  substituted alkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$  phenylalkyl,  $C_7$  to  $C_{16}$  substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;


which comprises:

refluxing



with ethanol to produce a solution;

adding an isothiocyanate comprised of the formula of:



wherein  $R = C_1$  to  $C_6$  alkyl,  $C_2$  to  $C_6$  substituted alkyl,  $C_2$  to  $C_{10}$  alkenyl,  $C_2$  to  $C_{10}$  substituted alkenyl,  $C_3$  to  $C_7$  cycloalkyl,  $C_3$  to  $C_7$  substituted cycloalkyl, phenyl, substituted phenyl,  $C_7$  to  $C_{16}$


phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;

to the solution to form a reaction mixture;

cooling the reaction mixture;

filtering the reaction mixture to produce **III**.


20. A method for producing an antimycobacterial compound comprising the formula of:



wherein R<sub>1</sub> = C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>10</sub> substituted alkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;

which comprises:


adding diethyl ether to



to produce a solution;

boiling the solution;

adding a carboxylic acid anhydride comprising the formula of:



wherein R= C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> substituted alkyl, C<sub>2</sub> to C<sub>10</sub> alkenyl, C<sub>2</sub> to C<sub>10</sub> substituted alkenyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, C<sub>3</sub> to C<sub>7</sub> substituted cycloalkyl, phenyl, substituted phenyl, C<sub>7</sub> to C<sub>16</sub> phenylalkyl, C<sub>7</sub> to C<sub>16</sub> substituted phenylalkyl, benzyl, substituted benzyl, naphthyl, substituted naphthyl, heterocycle, substituted heterocycle;

in ether to the solution to form a reaction mixture;

refluxing the reaction mixture;

cooling the reaction mixture to produce **IV**.

## Abstract

The present invention relates to novel antimycobacterial compounds and in particular to antimycobacterial compounds comprised of Schiff base, diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

# MODIFICATIONS OF LIPOPHILICITY





Fig 1

# Mouse Data, Spleen



\* 1 dead at each 11, 17, 18 and 22 days post-infection

\*\* 1 dead at 9 days post-infection

\*\*\* 1 dead at 11 days post-infection

Fig. 2